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Background: Insulin resistance may play a pathogenic role in cardiovascular 
disease (CVD). Resistance to insulin has been associated with obesity, hypertension, 
and abnormal glucose and lipid metabolism. The constellation of these features among 
insulin resistant subjects has been called the metabolic syndrome. Prevalence of the 
metabolic syndrome increases with age and is most common in the elderly. Different 
criteria have been proposed to define the metabolic syndrome (ATP, WHO, AACE, 
EGIR). Current management of metabolic syndrome focuses on the specific risk factors 
  xviii
that the patient may have without targeting the underlying insulin resistance. 
Angiotensin Converting Enzyme Inhibitors (ACEI) and Angiotensin Receptor Blockers 
(ARB) are widely used antihypertensive medications that may improve insulin 
sensitivity. We hypothesize that they can be used to reduce the long term cardiovascular 
complications in elderly hypertensive subjects with evidence of insulin resistance. In 
this study, we determined the effect of ACEI/ARB on the long term development of 
CVD in hypertensive non-diabetic elderly patients with the metabolic syndrome, as well 
as in patients with insulin resistance. Methods: Our research project utilizes the 
Cardiovascular Health Study (CHS) dataset. This dataset is a community based 
observational study where elderly participants were randomly selected and followed up 
for 11 years and the time to any cardiovascular event was recorded. In our project, we 
included hypertensive, non-diabetic individuals, with evidence of metabolic syndrome 
or insulin resistance, but had not experienced cardiovascular events at baseline. Cox 
regression model was used to evaluate the effect of ACEI/ARB on the time to the first 
cardiovascular event compared to the other antihypertensive medications adjusting for 
possible confounders such as age, race, gender, smoking status, triglycerides, LDL 
levels, systolic blood pressure, development of diabetes, congestive heart failure (CHF) 
and the number of anti-hypertensives. Results: In elderly hypertensive non-diabetic 
subjects with the metabolic syndrome according to the ATP and the WHO criteria, the 
hazard ratio for CVD associated with the use of ACEI/ARB was 0.65 or 0.68 (with 95 
% C.I. of [0.45, 0.98], and [0.48, 0.96]) respectively when compared to the group 
exposed to the other anti-hypertensives. When the metabolic syndrome was defined 
  xix
according to the AACE and EGIR, the use of ACE/ARB was associated with hazard 
ratios for CVD equal to 0.74 and 0.899, respectively (with 95 % C.I. of [0.54, 1.09] and 
[0.61, 1.34]) compared to the use of the other anti-hypertensives. Hypertensive non-
diabetic elderly subjects who were insulin resistant as evidenced by a HOMA-IR in the 
upper quartile, had a hazard ratio for CVD of 0.78 (95 % C.I. [0.56, 1.09]) associated 
with the use of ACEI/ARB compared to the use of other anti-hypertensives. 
Conclusions: The effect of ACEI/ARB on the development of cardiovascular events 
differs according to the definition of the metabolic syndrome. Elderly hypertensive 
patients with the metabolic syndrome, defined by ATP and WHO, seem to have lower 
risk of CVD with ACEI/ARB compared to the other antihypertensive medications. 
However, this association is not significant in elderly hypertensive patients in the upper 
quartile of HOMA and in patients with the metabolic syndrome as defined by AACE 
and EGIR criteria. 
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CHAPTER I 
Background 
Overview of the Document 
 
This dissertation describes a study designed to examine the effect of 
ACEI/ARB on the cardiovascular sequelae in hypertensive non-diabetic elderly 
subjects with the metabolic syndrome or evidence of insulin resistance. This chapter 
provides background information necessary to understand the significance of the 
project. The second chapter presents the objective, central hypothesis, rationale, 
specific aims and significance of the project. Chapter 3 describes the methodology 
used to conduct the study. The results are presented in chapter 4 followed by a 
discussion of the results and concluding remarks in chapter 5. 
Definition of Metabolic Syndrome 
 
The metabolic syndrome, or insulin resistance syndrome, is the constellation of 
different metabolic risk factors which promotes the risk for the development not only 
of diabetes but also of cardiovascular events as shown by several population based 
studies (1-8).  
There is no uniform definition for the metabolic syndrome and different 
criteria have been proposed (9): 
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World Health Organization (WHO) Criteria 
Based on the WHO, a diagnosis of the metabolic syndrome is made if the 
patient shows one of several markers of insulin resistance (10):  
 impaired fasting glucose (fasting glucose level between 110-125 mg/dl),  
 impaired glucose tolerance (2-hr post glucose level between 140-200 
mg/dl),  
 being in the upper quartile of the HOMA-IR level for the study population  
AND  
2 of the following additional risk factors:  
 Obesity (waist to hip ratio > 0.9 in men or waist to hip ratio > 0.85 in women 
and/ or body mass index [BMI] > 30 kg/m2), or 
 High triglycerides level ≥ 150 mg/dl or  
 HDL-C < 35 mg/dl in men or  < 39 mg/dl in women, or 
 Blood pressure ≥ 140 mm Hg for systolic blood pressure (SBP) and ≥ 90 mm 
Hg for diastolic blood pressure (DBP)  
 Microalbuminuria (albumin excretion > 20 mcg/min). 
European Group for Study of Insulin Resistance (EGIR) criteria 
The EGIR proposed a modification of the WHO definition (11). By their 
criteria, plasma insulin level in the upper quartile of the study population plus 2 
additional risk factors constitutes a diagnosis of the syndrome. The risk factors 
include:  
 high waist circumference ( ≥ 94 cm in men or ≥ 80 cm in men), or 
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 high triglycerides level (≥ 150 mg/dl), or 
 low HDL-C level (< 39 mg/dl in men or women), or 
 high blood pressure (≥ 140/90 mm Hg or on hypertension medications), or 
 impaired glucose metabolism (impaired glucose tolerance or impaired 
fasting glucose). 
National Cholesterol Education Program (NCEP)’s Adult Treatment Panel III 
(ATP III) criteria 
 
The most widely used definition for the metabolic syndrome was established 
by NCEP’s ATP III report in 2001 (12). These guidelines were subsequently updated 
in 2005 by a scientific statement jointly published by the American Heart Association 
(AHA) and the National Heart Lung and Blood Institute (NHLBI) (9). A diagnosis of 
metabolic syndrome is defined in the updated guidelines as a person meeting 3 of the 
following 5 conditions: waist circumference > 102 cm in men or > 88 cm in women, 
triglycerides ≥ 150 mg/dl or on drug treatment for elevated triglycerides, HDL-C < 40 
mg/dl in men or < 50 mg/dl in women or on drug treatment for reduced HDL-C, blood 
pressure ≥ 130 mm Hg for SBP or ≥ 85 mm Hg for DBP or on antihypertensive 
treatment in a patient with a history of hypertension, fasting glucose ≥ 100 mg/dl or on 
drug treatment for elevated glucose. The ATP criteria are simple to use in a clinical 
setting and have the advantage of avoiding emphasis on a single cause for the 
metabolic syndrome. 
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American Association of Clinical Endocrinologists (AACE) criteria 
The AACE modified the ATP Ш criteria (13). According to AACE, a patient 
is defined to have the syndrome if he/she is at increased risk of insulin resistance by 
having any of the following risk factors based on clinical judgment: 
 Family history of cardiovascular diseases (CVD) or  
 a sedentary lifestyle (low or minimal exercise intensity) or  
 high BMI ( > 25 kg/m2) or 
 increased waist circumference (> 40 inches in men or > 35 inches in 
women) 
And if he/she has 2 of the 4 identifying abnormalities:  
 high triglycerides level (≥ 150 mg/dl),  
 low HDL-C (< 40 mg/dl in men or < 50 mg/dl in women),  
 high blood pressure (≥ 130/85 mm Hg), 
 Impaired fasting glucose or impaired glucose tolerance. 
International Diabetes Foundation (IDF) criteria 
The IDF provided different criteria for the metabolic syndrome in 2005 (14). 
The IDF set out ethnic-specific criteria for increased weight circumference (≥ 94 cm 
in men or ≥ 80 cm in women for people of European origin; ≥ 90 cm in men or ≥ 80 
cm in women in Asian populations, except for Japan, in whom the criteria were ≥ 85 
cm in Japanese men or ≥ 90 cm in Japanese women). According to the IDF, a person 
is diagnosed with the metabolic syndrome if he/she has an increased waist 
circumference plus 2 additional risk factors:  
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 high triglycerides level (≥ 150 mg/dl or on medications for the 
hypertriglyceridemia), 
 low HDL-C (< 40 mg/dl in men or < 50 mg/dl in women or on medications 
for the low HDL level),  
 high blood pressure (≥ 130/85 or on hypertension medications), 
 high fasting glucose level (≥ 100 mg/dl). 
Prevalence of the Metabolic Syndrome 
 
Estimates of the prevalence of the metabolic syndrome have varied 
substantially due to the variability of evaluated population and diagnostic criteria. The 
metabolic syndrome, as defined by the AHA/NHLBI/ATP III criteria, is estimated to 
be prevalent in 28% of the US adults aged ≥ 20 years, as found by a representative 
sample who participated in the cross-sectional NHANES III survey (1988-1994) (15). 
The prevalence increased significantly to 31.9 % in the NHANES (1999-2000) survey 
indicating that it continues to rise.  
The prevalence of the metabolic syndrome increases with age, reaching peak 
levels in the sixth decade for men and the seventh decade for women (16). According 
to NHANES III survey, the prevalence of the metabolic syndrome was 6.7% among 
participants 20-29 years old, 43.9% among participants 60-69 years old, and 42% 
among participants 70 years and older. This increased prevalence of metabolic 
syndrome with age is paralleled with similar increases in the prevalence of obesity, 
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insulin resistance, dyslipidemia, high blood pressure and impaired glucose 
metabolism. 
The prevalence of the metabolic syndrome, as defined by the ATP Ш criteria, 
was found to vary among ethnic groups ranging from a low 13.9 % in black men 
(mean age = 40.9 years) to a high of 27.2 % in Mexican American women (mean age 
= 38.9 years) (16). These findings suggest that Mexican Americans are more prone to 
develop insulin resistance, abnormal body fat distribution and metabolic syndrome 
(16-18). On the other hand, the African American population is known to have higher 
insulin resistance, higher CHD mortality rate and higher incidence of type 2 diabetes 
compared to the Caucasians. However, the metabolic syndrome prevalence was lowest 
in African American men accompanied with lower prevalence of large waist 
circumference, high triglycerides levels, low HDL levels but higher prevalence of 
high blood pressure (16). These findings may raise questions regarding the predictive 
validity of the ATP Ш criteria across different ethnic groups. 
Pathogenesis of the Metabolic Syndrome 
 
The pathogenesis of the metabolic syndrome is complex and incompletely 
understood but obesity and insulin resistance are known to contribute to its 
development (19). Insulin is normally responsible for the decrease in hepatic glucose 
production and the increase in insulin stimulated glucose uptake. In insulin resistance, 
the phosphatidyl inositol-3 (PI-3) kinase pathway, which is responsible for the 
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metabolic effects of insulin, is defective leading to hyperglycemia and compensatory 
hyperinsulinemia (20).  
The P1-3 kinase pathway increases nitric oxide level which is a potent 
vasodilator. Thus, the impairment of this pathway in insulin resistance contributes to 
vascular endothelial dysfunction. Another signal transduction pathway of insulin 
involves the ERK-MAP kinase, which stimulates smooth muscle growth and 
proliferation, maintains its sensitivity to insulin. The overall effect may lead to 
atherogenesis (20;21). The atherogenic effects of insulin resistance may also result 
from increased production of very low density lipoproteins (VLDL), increased platelet 
activation and increased levels of coagulation factors such as fibrinogen and 
plasminogen activator inhibitor (22;23). 
In insulin resistance, the adipocytes show resistance to the anti-lipolytic effects 
of insulin and results in an increase in the level of free fatty acids (FFA) in plasma. 
Overabundance of FFA exacerbates the existing insulin resistance by inhibiting 
insulin mediated glucose uptake in insulin sensitive tissues (22). In addition, these 
FFA cause an increased production of glucose, triglycerides and VLDL. High 
circulating glucose and FFA levels increase pancreatic insulin secretion resulting in 
hyperinsulinemia which may predispose to the development of high blood pressure by 
different mechanisms such as enhancing renal sodium and water reabsorption, and 
increasing sympathetic nervous system stimulation (22;23). Thus, the result would be 
the constellation of the metabolic abnormalities in an individual more than can be 
expected by chance.  
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Estimate of the Associated Risk of Cardiovascular Sequelae 
Associated with the Metabolic Syndrome 
 
Numerous studies reported a significant increase in the hazard of CHD 
mortality, CVD mortality and all-cause mortality in patients with the metabolic 
syndrome (2-4). However, because of the different definitions of the metabolic 
syndrome, the magnitude and impact of cardiovascular risk is difficult to assess. Most 
estimates for the hazard for mortality associated with the metabolic syndrome ranged 
from 1.5 to 3 (2;4), although, higher estimates for CHD mortality (around 4) have also 
been reported (3). Increased risks of mortality were observed for diabetic subjects and 
in subjects with preexisting CVD (diseases that include coronary and non-coronary 
heart diseases such as stroke, and peripheral vascular diseases) with the highest risk 
among those with both diabetes and CVD. The risk of developing incident CHD in 
non-diabetic subjects with metabolic syndrome ranges from 1.3-2.9 (5;6;24).  
Surrogate Measures of Insulin Resistance 
 
Many investigators have used the diagnosis of the metabolic syndrome in 
individuals as an indicator of insulin resistance. Insulin resistance is also assessed by 
dynamic and static methods (25). Dynamic measures of insulin resistance, such as the 
euglycemic clamp, is labor intensive and are not suitable for studying large numbers 
of patients (25). In many epidemiological studies, the homeostatic model assessment 
(HOMA) was used (26). HOMA is a method used to assess insulin resistance from 
basal glucose and insulin concentrations (27). The relationship between fasting plasma 
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glucose and insulin reflects the balance between hepatic glucose output and insulin 
secretion, which is maintained by a feedback loop between the liver and the pancreatic 
β cells. Plasma glucose concentration in the basal state is regulated by hepatic glucose 
output, which is insulin dependent. Insulin concentration is dependent on the response 
of pancreatic cells to glucose. Insulin signals glucose uptake in the fat and muscle 
tissues, which depends on circulating glucose level as well. However, glucose uptake 
in the brain and urine depends solely on glucose (28).  
HOMA can be calculated by multiplying fasting plasma glucose (mg/dl) and 
fasting plasma insulin (µU/ml) and dividing over 22.5 (27). Insulin sensitivity 
decreases as the HOMA value increases as shown in figure 1.1 below. There are good 
correlations between estimates of insulin resistance derived from HOMA and from the 
gold standard euglycemic clamp (26;27;29;30) and between HOMA and the minimal 
model (31;32). HOMA as well as the other measures (fasting insulin and fasting 
glucose/fasting insulin ratio) can indicate insulin resistance in subjects with normal 
glucose levels. As insulin resistance increases, fasting insulin and HOMA values 
increase, while the fasting glucose/insulin ratio decreases. On the other hand, HOMA 
but not fasting insulin or fasting glucose/insulin can reflect insulin resistance in 
diabetic subjects. Therefore, as the insulin resistance increases, HOMA value 
increases but no indicative changes are associated with fasting insulin or the fasting 
glucose/insulin ratio (table 1.1). 
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Figure 1.1: Relationship between HOMA level, insulin sensitivity and pancreatic 
β cell function (28) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1.1: Comparison between hypothetical HOMA level, fasting insulin and fasting 
glucose/insulin ratios in normoglycemic and diabetic subjects (33) 
 
Patient 
Hypothetical 
fasting serum 
values 
Fasting 
insulin 
measure 
Fasting 
glucose/fasting 
insulin ratio 
HOMA 
value 
A 
(normoglycemic) 
Fasting insulin  
20 (U/ml) 
Fasting glucose  
100 (mg/dl) 
20 5.0 4.94 
B 
(normoglycemic) 
Fasting insulin  
30 (U/ml) 
Fasting glucose  
100 (mg/dl) 
30 3.33 7.41 
C  
(diabetic) 
Fasting insulin  
30 (U/ml) 
Fasting glucose  
150 (mg/dl) 
30 5.0 11.11 
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Inhibition of Renin-Angiotensin-Aldosterone System and 
Insulin Resistance 
Several lines of evidence suggest that Angiotensin Converting Enzyme 
Inhibitors (ACEI) and Angiotensin Receptor Blockers (ARB) may improve insulin 
sensitivity and decrease the risk of type 2 diabetes. Acute and chronic administrations 
of ACEI and/ or ARB have been shown to improve insulin sensitivity in several 
studies (34-54), although a few studies reported a metabolically neutral effect (55;56). 
Several different mechanisms have been suggested. A summary of the studies that 
investigated the effect of ACEI/ARB on the development of new onset diabetes are 
shown in table 1.2 below. 
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Table 1.2: Effect of ACEI/ARB on the development of diabetes 
 
RCT = randomized controlled trial 
A recent meta-analysis reviewed the literature until 2006 and included 22 
clinical trials and 143,153 subjects (65). This meta-analysis found that ACEI/ARB 
were associated with the lowest incidence of diabetes compared to the other anti-
hypertensives. The use of diuretics was used as the standard of comparison. The odds 
ratio for ARB was 0.57 (95% CI [0.46, 0.72], p < 0.0001), 0.67 for ACEI (95 % C.I. 
[0.56, 0.80], p < 0.0001), 0.75 for those using calcium channel blockers (95 % C.I. 
Author Type of study 
Sample 
size 
Duration 
Characteristics 
of subjects 
Comparison 
Development 
of Diabetes 
Mcquen 
(57) 
RCT 
(HOPE) 
9,297 5 years At risk for CVD 
Ramipril vs. 
placebo 
↓ 
Nikalson 
(58) 
RCT 
(CAPP) 
10,413 6.1 years Hypertension 
Captopril vs. 
diuretic &/or 
beta blocker 
↓ 
Dahlof 
(59) 
RCT  
(LIFE) 
9,193 4.8 years Hypertension 
Losartan vs. 
Atenolol 
↓ 
Yusuf 
(60) 
RCT 
(CHARM) 
5,436 2-4 years Heart failure 
Candesartan 
vs. placebo 
↓ 
Cooper- 
Dehoff 
(61) 
RCT 
(INVEST) 
16,176 2.8 years 
Coronary artery 
disease 
Addition of 
Trandolapril to 
Verapamil 
↓ 
Kjeldsen 
(62) 
 
RCT 
(VALUE) 
9,995 4.2 years Hypertension 
Valsartan vs. 
Amlodipine 
↓ 
Barzilay 
(63) 
 
RCT 
(ALLHAT) 
18,411 4.9 years 
Hypertension + 
1 other risk 
factor 
Lisinopril vs. 
Amlodipine vs. 
Chlorthalidone 
↓ 
Bosch 
(55) 
RCT 
(DREAM) 5,269 3 years IFG, IGT 
Ramipril vs. 
placebo ↔ 
Vermens 
(64) 
Retrospective 
cohort 
 (SOLVD) 
291 ___ 
Left Ventricular 
dysfunction 
Enalapril vs. 
placebo 
↓ 
Taylor 
(56) 
Prospective  
cohort 
41,193  
 
8-16 
years 
Old women with 
hypertension 
 
ACEI  
vs. others 
↔ 
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[0.62, 0.90], p = 0.002), 0.90 for beta blocker (95 % C.I. [0.75, 1.09], p = 0.30), and 
0.77 for placebo (95 % C.I. [0.63, 0.94], p = 0.009). 
Different potential anti-diabetic mechanisms for ACEI and ARB have been 
suggested. Blockade of the renin-angiotensin system inhibition may lead to the 
reduced production of angiotensin П, limiting its negative effects on insulin signaling, 
tissue blood flow, oxidative stress, sympathetic activity, and adipogenesis (66).  
ACEI may reduce angiotensin П mediated vasoconstriction and thus increase 
the perfusion of skeletal muscles and the pancreatic islet β cells leading to increased 
insulin wash out from the pancreas and improved delivery of glucose and insulin to 
periphery (67). In addition, ACEI can decrease the local pancreatic renin-angiotensin 
system activation caused by the toxic effects of hyperglycemia, obesity, 
hyperlipidemia, and hypertension on the islet pancreatic cells (68-70). These toxic 
effects may involve islet cell damage, fibrosis and apoptosis. ACEI and ARB inhibit 
NAPDH oxidase, an enzyme that promotes oxidative stress which is stimulated by 
angiotensin П (71-73). Therefore, reduction of oxidative stress by reducing the 
formation and/ or the action of angiotensin П can reduce the pancreatic fibrosis and 
preserve the islet cell architecture. 
Angiotensin П administration to rats has led to inhibition of the insulin 
stimulated PI-3 kinase activity, which is responsible for the metabolic effects of 
insulin signaling (74). It is therefore predicted that ACEI/ARB may improve the 
insulin sensitivity by abrogating these inhibitory effects of Angiotensin П on insulin 
signaling. 
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Furthermore, the renin-angiotensin system inhibition might increase the levels 
of adiponectin and leptin. (75). These hormones are believed to enhance insulin 
sensitivity, promote the differentiation of adipocytes and possess complimentary and 
possible additive effects on weight reduction. In addition, ACEI and ARB have been 
shown to increase the cellular expression of glucose transporter protein (GLUT-4) 
which results in enhanced insulin stimulated glucose transport activity of the skeletal 
muscles (76;77). 
Some molecules of the ACEI or ARB may have metabolic effects that differ 
between and within drug classes, suggesting anti-diabetic mechanisms that go beyond 
the effect on the inhibition of the renin-angiotensin system. It has been suggested that 
some ARB agents, such as telmisartan, have a partial agonistic activity of the 
peroxisome proliferator activated receptors (PPARγ) (78). PPARγ plays an important 
role in the regulation of carbohydrate and lipid metabolism and can improve insulin 
sensitivity (79;80).  
Some of the effects of ACEI but not ARB may be explained by increased 
levels of bradykinin, which is a potent dilator and modulator of insulin action as a 
result of inhibiting angiotensin converting enzyme (67). It has been suggested that 
bradykinin enhances insulin signaling (81) and translocation of the glucose transporter 
(GLUT-4) in skeletal muscle (82;83). In addition, bradykinin directly increases NO 
levels which enhance insulin stimulated glucose oxidation and transport (84;85).  
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Inhibition of Renin-Angiotensin-Aldosterone System and 
Atherosclerosis/ CVD 
 
Inhibition of the renin-angiotensin system has been definitely shown to reduce 
the morbidity and mortality associated with heart failure, myocardial infarction (MI) 
and to reduce cardiovascular events associated with diabetes (86). Currently, the use 
of ACEI or ARB is a well established treatment plan for hypertensive diabetic 
patients. The effect of the renin-angiotensin system on the progression of coronary 
atherosclerosis may be due to its influence on the fibrinolytic balance, vascular 
endothelial function, inflammation and plaque instability (86). 
It is documented that renin-angiotensin system inhibition would ameliorate the 
risk of atherosclerosis in animal models. Treatment with different ACEI reduced 
endothelial dysfunction in atherogenic diet fed (87) and in hyperlipidemic rabbits (88). 
Similarly, ARB reduced blood pressure and atherosclerosis in different animal models 
(89-92). In a study of mice with the metabolic syndrome, treatment with ARBs 
inhibited development of hyperinsulinemia, hypertension, obesity, cardiac 
hypertrophy and atherosclerosis (93). 
Beside the documented beneficial effect of ACEI in patients with reduced left 
ventricular function, ACEIs seem to have beneficial effects in decreasing 
cardiovascular events in stable patients without heart failure or left ventricular systolic 
dysfunction but with high risk coronary atherosclerosis as found in the HOPE and 
EUROPA studies (57;94). The HOPE study was a large randomized controlled trial 
that was designed to test the hypothesis that ACEI (Ramipril) would improve 
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morbidity and mortality in patients at high CVD risk (age > 55 years old, preexisting 
CVD, cigarette smoking, hypertension, or high cholesterol) compared to placebo. The 
trial was stopped early because of convincing evidence of the benefit of ACEI on the 
cardiovascular death, non fatal MI and stroke. The reduction in these endpoints far 
exceeded the modest reduction in blood pressure. The EUROPA study was a large 
double-blind placebo controlled multicenter trial that intended to investigate the effect 
of ACEI in the low risk population with stable CHD and no apparent heart failure. The 
results of the EUROPA study showed that among this subgroup of patients, ACEI can 
significantly improve the cardiovascular outcome including cardiovascular death, MI 
or cardiac arrest. Thus, treatment of ACEI should be considered in all patients with 
CHD. 
A few clinical studies, such as the PEACE (95) and ALLHAT (96), found no 
significant decrease in the cardiovascular endpoint in subjects randomized to ACEI. A 
subgroup analysis of the ALLHAT study, a randomized double-blind hypertension 
treatment trial compared the effect of an ACEI (Lisinopril) to a thiazide type diuretic 
(Chlorthalidone) on the cardiovascular outcomes in hypertensive subjects with and 
without the metabolic syndrome. African American participants with the metabolic 
syndrome who were randomized to Lisinopril compared to Chlorthalidone were more 
likely to have higher rates of combined CHD, CVD, stroke, heart failure and ESRD, 
whereas non-African American participants with the metabolic syndrome had higher 
rates of only combined CVD and heart failure. There were no significant differences 
in endpoints for Lisinopril compared to Chlorthalidone in subjects without the 
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metabolic syndrome. The PEACE trial was a double blinded placebo controlled study 
that tested the hypothesis that the addition of ACEI in patients with stable coronary 
artery disease and normal or slightly reduced left ventricular function might reduce 
future cardiovascular complications. After a median follow-up of about 4.8 years, 
patients randomized to trandolapril (ACEI) showed no further benefit in terms of 
death from CVD, MI and coronary revascularization.  
The ALLHAT study was the first and only study to report detrimental effects 
of ACEI/ARB on the cardiovascular clinical endpoints including heart failure, CVD, 
and CHD. A combined analysis of the three largest clinical trials (PEACE, HOPE and 
EUROPA) that investigated the effect of ACEI in patients with no evidence of heart 
failure was performed (97). This systematic review of these trials showed a clear 
benefit for the use of ACEI for a range of cardiovascular outcomes. It has been 
suggested that the apparent neutral effects of the PEACE trial could have been due to 
the inadequate power of that study.  
A meta-analysis of most of the pertinent trials of ACEI in patients with 
coronary atherosclerosis found a modest beneficial effect of ACEI in patients with 
coronary artery disease and preserved ventricular function on combined 
cardiovascular outcome used in these studies (98). Compared to placebo, the use of 
ACEI was associated with a decrease in cardiovascular mortality (relative risk 0.83, 
95% C.I. [0.72, 0.96]), non-fatal MI (relative risk 0.84, 95% C.I. [0.75, 0.94]), all 
cause mortality (relative risk 0.87, 95% CI [0.81, 0.94]) and revascularization rates 
(relative risk 0.93, 95% C.I. [0.87, 1.00]). Treatment of 100 patients at risk for CVD 
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with ACEI or ARB for an average of 4.4 years could prevent one death, or one MI, or 
one cardiovascular death or one coronary revascularization procedure. 
Current Gaps of Knowledge in the Literature 
 
Currently, antihypertensive medications, but no specific drug therapy, are 
recommended for elderly hypertensive non-diabetic patients with metabolic 
syndrome or insulin resistance. Most of the major clinical studies that investigated 
the effect of ACEI/ARB on incidence of diabetes or cardiovascular events had a 
mean age for participants less than 65 years old (99). Taking into consideration that 
the elderly population is at high CVD risk with a very high prevalence of the 
metabolic syndrome, there is a need for studies that are intended to investigate the 
effect of these medications specifically in the elderly population. 
Most studies reported the effect of inhibition of renin-angiotensin system on 
the cardiovascular events in hypertensive patients at risk of CVD included diabetic 
subjects. The effect of ACEI/ARB in diabetic subjects is well-established. Thus, 
there is a need for studies designed to investigate the effect of ACEI/ARB in non-
diabetic hypertensive subjects who are at high CVD risk such as the subjects with 
evidence of insulin resistance or metabolic syndrome. Few studies reported the effect 
of ACEI/ARB in subjects with the metabolic syndrome (100;101). These studies 
included small sample size that was followed up for a short duration of time. In 
addition, the effect of ACEI/ARB on the clinical cardiovascular endpoints was not 
assessed. 
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Summary of Background 
 
The metabolic syndrome is a highly prevalent disorder that increases the 
CVD risk. Insulin resistance is hypothesized to be the major underlying risk factor 
for the development of metabolic syndrome. Current management of the metabolic 
syndrome focuses on the specific risk factors without targeting the underlying 
insulin resistance. Inhibition of the renin-angiotensin system by ACEI/ARB may 
decrease insulin resistance, reduce atherosclerosis and reduce CVD risk. The 
beneficial effects of ACEI/ARB are well established in diabetic patients; however 
whether this drug class also improves cardiovascular outcomes in non-diabetic 
hypertensive patients with insulin resistance is yet to be investigated. The metabolic 
syndrome is a highly prevalent disorder in subjects older than 65 years old which 
necessitates the investigation of the effect of ACEI/ARB in elderly hypertensive 
non-diabetic subjects with metabolic syndrome or evidence of insulin resistance. 
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CHAPTER II 
Specific Aims and Significance 
Goals and Objectives 
 
Our long term goal is to find strategies to manage insulin resistance and to 
prevent its development in patients at risk which will lead to lower incidence of type 2 
diabetes and cardiovascular events. The objective of this research project is to 
investigate the relationship between the use of renin-angiotensin-aldosterone system 
inhibitors such as ACEI or ARB and the incidence of cardiovascular events in elderly 
hypertensive, non-diabetic patients with the metabolic syndrome, or insulin resistance 
(defined as being in the upper quartile of the HOMA-IR)  
Central Hypothesis 
 
The central hypothesis is that ACEI/ARB will reduce incident cardiovascular 
events in elderly hypertensive non-diabetic individuals with the metabolic syndrome 
or insulin resistance, as compared to other anti-hypertensives.  
Rationale 
 
The rationale for the proposed research is that ACEI and ARB may have a 
beneficial effect on the insulin sensitivity. Clinical evidence also suggests that ACE 
and ARB, when compared to the other antihypertensive agents, may be associated 
with the lowest risk of incident diabetes. The HOPE study has further provided 
additional evidence that ACEI/ARB reduced the risk of cardiovascular events and new 
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onset diabetes in patients at risk. Currently, the use of ACEI or ARB is a well 
established treatment plan for hypertensive diabetic patients. However, the effect of 
ACEI or ARB is not established in hypertensive, non-diabetic elderly patients with 
evidence of insulin resistance. 
Specific Aims 
 
We tested our hypothesis with the following specific aims: 
Specific aim 1: Identify the effect of ACEI /ARB on the long term development of 
cardiovascular events in elderly non-diabetic hypertensive patients with metabolic 
syndrome. 
The working hypothesis here is that ACEI/ARB reduces incident 
cardiovascular events in elderly hypertensive patients with the metabolic syndrome. 
Several definitions of the metabolic syndrome were evaluated, including the WHO, 
EGIR, ATP Ш, and AACE criteria. 
Specific aim 2: Identify the effect of ACEI /ARB on the long term development of 
cardiovascular events in elderly non-diabetic hypertensive patients with insulin 
resistance. 
The working hypothesis here is that ACEI/ARB reduces incident 
cardiovascular events in elderly hypertensive patients with insulin resistance. Presence 
of insulin resistance was defined by HOMA-IR values in the upper 75th percentile of 
the study population. 
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The proposed work is important because it focuses on a specific treatment 
approach for hypertensive, non-diabetic elderly patients with evidence of insulin 
resistance. The combination of work proposed in aims 1 and 2 is expected to identify 
the effect of ACEI/ARB on the long term cardiovascular events in these patients. Such 
results will have a positive impact because it would propose a treatment approach that 
is expected to reduce the long term cardiovascular effects of insulin resistance. 
Significance of the Proposed Research 
 
The metabolic syndrome and insulin resistance are highly prevalent in the 
elderly. Currently the management of metabolic syndrome focuses on lifestyle 
modifications such as weight reduction, smoking cessation, exercise and reduced 
intake of atherogenic diet. Recommendations for drug therapy are based on current 
guidelines for the presence of specific metabolic risk factors according to the AHA, 
NHLBI, and American Diabetes Association (ADA). For the hypertension risk factor, 
anti-hypertensives are recommended. However, no specific drug therapy is 
recommended for the hypertensive patients with evidence of insulin resistance. 
Inhibition of the renin-angiotensin system by ACEI or ARB has been shown to be 
associated with improving insulin sensitivity. The beneficial effects of ACEI/ARB are 
well established in diabetic patients; however whether this drug class also improves 
cardiovascular outcomes in non-diabetic elderly patients with insulin resistance is yet 
to be investigated. By conducting our specific aims, we expect to provide evidence for 
the use of ACEI/ARB specifically in hypertensive, non-diabetic elderly patients with 
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evidence of insulin resistance. The proposed research is significant because, if 
expected results on reduction in incident cardiovascular events are observed, ACEI 
and ARBs would be a valid antihypertensive option not only in diabetic patients, but 
also in non-diabetic hypertensive elderly patients with insulin resistance. An 
important advance in the management of the metabolic syndrome is expected, along 
with reduced long term complications and health care costs. Furthermore, based on the 
expected results of this proposal, future studies may also assess the use of ACEI 
and/or ARB in preventing the development of metabolic syndrome in patients at risk. 
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CHAPTER III 
Methods  
Specific Aim 1 
Identify the effect of ACEI /ARB on the long term development of cardiovascular 
events in elderly non-diabetic hypertensive patients with metabolic syndrome. 
Introduction 
Insulin resistance plays a pathogenic role in cardiovascular events. Better 
strategies to manage the insulin resistance may lower the incidence of the long term 
fatal complications. The objective of this aim is to investigate the relationship between 
the use of renin-angiotensin-aldosterone system inhibition by ACEI or ARB and the 
incidence of cardiovascular events in elderly hypertensive, non-diabetic patients with 
evidence of insulin resistance. To attain the objective of this section, we tested the 
working hypothesis that ACEI/ARB would reduce incident cardiovascular events in 
elderly hypertensive patients with the metabolic syndrome. Four different studies were 
conducted. Each of these studies included a different definition of the metabolic 
syndrome. We utilized the Cardiovascular Health Study (CHS) database which is a 
longitudinal observational study that followed up the participants for development of 
cardiovascular events over a period of 15 years. It was expected that the inhibition of 
the renin-angiotensin-aldosterone system would be associated with lower incidence of 
the long term cardiovascular complications of the metabolic syndrome. Such a finding 
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would be of importance because it would allow for the development of an effective 
approach to manage hypertensive patients with the metabolic syndrome and reduce their 
long term cardiovascular complications. 
Rationale 
 
The rationale behind testing this specific aim is that ACEI and ARB are known 
to have beneficial effects on insulin sensitivity and incidence of diabetes compared to 
other anti-hypertensives. Insulin resistance has been proposed as an important 
underlying cause for the metabolic syndrome and is associated with subsequent CVD 
(102;103). Thus, by reducing insulin resistance, ACEI and ARB may reduce CVD risk 
in hypertensive subjects with the metabolic syndrome. We are particularly interested in 
elderly subjects with the metabolic syndrome in this aim because the metabolic 
syndrome is highly prevalent in the elderly population. Therefore, we expect that the 
hypertensive elderly non-diabetic patients with metabolic syndrome who were 
prescribed ACEI or ARB to have a lower incidence of cardiovascular events when 
compared to the control group who were prescribed other antihypertensive drugs. 
Several definitions of the metabolic syndrome exist. Therefore, 4 separate studies were 
conducted; each of which used one of 4 different criteria proposed for the clinical 
diagnosis of the metabolic syndrome. 
Design 
 
This study was a retrospective cohort study that utilized the CHS Database. The 
subjects included in the analysis were non-diabetic and had been prescribed any 
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antihypertensive medication during any of the follow-up years. In addition, these 
subjects met one of 4 criteria for the metabolic syndrome. The subjects were identified 
based on their exposure to any ACEI or ARB. Hence, the exposed group was the 
subjects who had been exposed to ACEI/ARB alone or combined with other anti-
hypertensives and the control group represented the subjects who were exposed to other 
anti-hypertensives other than ACEI/ARB. The primary endpoint was defined as the 
development of any incident cardiovascular event (described on page 31). The primary 
and secondary endpoints occurrence rates (see page 31) were compared between the 
ACEI/ARB group and the other anti-hypertensives control group adjusting for the 
possible confounding factors. 
Data Source 
 
The CHS is a National Institute of Health (NIH) sponsored community-based, 
longitudinal observational study of adults aged 65 and older at baseline to evaluate risk 
factors for the development and progression of CVD. Participants were randomly 
selected from Medicare eligibility lists in 4 U.S. communities in North Carolina, 
California, Pennsylvania and Maryland. Subjects eligible for the CHS included those 
who were: 1) 65 years or older; 2) non-institutionalized individuals; 3) expected to 
remain in the area for 3 years; 4) able to give informed consent. Participants were 
eligible whether or not they had a history of CVD (104). The complete dataset is 
available from the NHLBI without cost. The study received approval from 
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investigational review boards at each site and the Data Coordinating Center at the 
University of Washington. 
An initial cohort of 5,201 was recruited between 1989 and 1990, and an 
additional 687 African Americans were recruited in 1992 and 1993. Of those contacted 
and eligible, 57.3% were enrolled. Self-reported health behaviors, history of disease, 
anthropometric measures, current medication use, seated blood pressure readings, 
electrocardiogram recordings, echocardiograms, and fasting blood chemistry measures 
were obtained during the baseline home interview or clinical examination. Blood was 
drawn in the morning after an overnight fast, and samples were analyzed in 
standardized fashion at the Central Blood Analysis Laboratory, University of Vermont. 
Follow-up interviews for cardiovascular events consisted of annual examinations and 
interim 6-month telephone calls for a total of 15 years. However, for the purpose of this 
study, we only used the first 11 years of event data (as explained in the section below). 
CVD included CHD, MI, angina pectoris, CHF, self-reported coronary artery bypass 
surgery (CABG), angioplasty, stroke and transient ischemic attack (TIA). For each 
cardiovascular condition, self-report was confirmed using components of the baseline 
examination or, if necessary, using a validation protocol that included review of medical 
records or surveys of treating physicians (105).  
Initial classifications of events or deaths were made by the Coordinating Center 
and the Field Centers. Events initially classified as cardiac endpoints (MI, angina, CHF, 
claudication) were adjudicated by the cardiac subcommittee while events initially 
classified as cerebrovascular endpoints (stroke, TIA) were adjudicated by the 
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cerebrovascular subcommittee. The committee included CHS investigators from each of 
the four field centers, the coordinating center, and the project office from the NHLBI. 
A packet of materials, with data summaries and support documents, for each 
event was prepared by the Coordinating Center and mailed to members of the 
appropriate review subcommittee prior to each meeting. If an event had been identified 
as both a cardiac and cerebrovascular endpoint, the packet for that event was sent to 
both review committees. During the adjudication meeting, the field center investigators 
presented the medical history, symptoms, course, and outcome of each event. The 
committee then discussed the case and determined the final classification. 
Inclusion /Exclusion Criteria, Covariates and Endpoint Definition 
 
Subjects included in the analysis for this proposal were based on the following 
inclusion and exclusion criteria to the CHS database. 
Inclusion Criteria: 
 Presence of the metabolic syndrome at baseline according to 4 different 
criteria explained below 
 Subjects who have used any antihypertensive medication at baseline or 
during any of the follow-up years 
Exclusion Criteria: 
 Baseline diagnosis of diabetes ( as defined by the ADA; fasting blood 
glucose > 126 mg/dl or a 2-hour serum glucose ≥ 200 mg/dl upon an oral 
glucose tolerance test with 75 gm glucose) or anti-diabetic medication use 
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including alpha glucosidase inhibitors, sulfonylureas, biguanides, 
thiazolinediones and insulin. 
 Subjects with any prior history of cardiovascular events (defined as: 
MI, CHF, CHD, claudication, stroke, TIA, angina and arrhythmia). These 
subjects were predisposed to recurrent events. Therefore, they were 
excluded from the study. 
Covariates and important variables to be considered: 
The following major risk factors for CHD were considered: age ≥ 45 years for 
males and ≥ 55 years for females, cigarette smoking, low HDL (< 40 mg/dl), family 
history of premature CHD (male first degree relative < 55 years old, female first degree 
relative < 65 years), and hypertension (blood pressure >140/90 mmHg or on 
antihypertensive therapy). In addition to these CHD risk factors, we also considered 
other important cardiovascular risk factors as covariates. In consideration of all these 
risk factors, the list of covariates included: 
 Age (age was recorded in the CHS dataset as a categorical variable 
with 13 levels, each level being a 2 year category, 1st level included age 
65-66; 2nd level included age 67-68, etc, except for the last 2 
categories) as shown in table 3.1 below.  
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Table 3.1: Age variable as recorded in the CHS dataset 
 
 
 
 
 
 
 
 
 
 Smoking status (current, former or never smoker) 
 Family history of cardiovascular events (present or absent) 
 Gender (male/female) 
 Alcohol use (defined as the number of alcohol beverages consumed per 
week): Different studies showed evidence indicating that moderate alcohol 
intake might be associated with a reduced incidence of CHD in diabetic 
and non-diabetic subjects (106;107). On the other hand, there is also 
substantial evidence that problem drinking (well beyond two drinks per 
day) is associated with increased cardiovascular mortality (106). 
 Exercise intensity: Physically active individuals generally show a 
reduced risk of CHD compared to the sedentary population (108-110). This 
variable is categorical with 4 levels: no exercise, low, moderate or high 
exercise. 
Value Age category 
1 65 - 66 
2 67- 68 
3 69 - 70 
4 71 - 72 
5 73 - 74 
6 75 - 76 
7 77- 78 
8 79 - 80 
9 81- 82 
10 83 - 84 
11 85 - 86 
12 87- 89 
13 >= 90 
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 Aspirin use (aspirin user or non user): A considerable number of 
subjects worldwide take aspirin on a daily basis for the prevention and 
treatment of CVD. Aspirin inhibits platelet activation by irreversibly 
inactivating cyclooxygenase-1, thereby blocking the generation of 
thromboxane A2, a potent
 vasoconstrictor and platelet agonist. The 2009 
version of the U.S. Preventive Services Task Force (USPSTF) 
recommendation encourages men who are between 45 to 79 years old and 
women between ages 55 to 79 years old to use aspirin when the potential 
benefit of a reduction in MI for men or stroke for women outweighs the 
potential harm of an increase in gastrointestinal hemorrhage (111). 
 BMI and waist circumference: Total body fat and adipose tissue 
distribution, measured by BMI and waist circumference, are associated 
with cardio-metabolic risk, yet there are conflicting data regarding the 
better predictor of cardiovascular risk (112). 
 Triglycerides: despite the debate regarding the role of triglycerides in 
CVD, some studies showed that the triglycerides level can serve as an 
independent cardiovascular risk factor after controlling for LDL, HDL 
(113). 
 HDL cholesterol (continuous variable) 
 LDL cholesterol (continuous variable) 
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 Race (white, African American or other): Due to the very small percent 
of subjects in the “other” category, the race variable was changed to a 
binary variable: African American or not.  
African Americans have the highest overall CHD mortality rate and 
the highest out-of-hospital coronary death rate of any ethnic group in the 
United States, particularly at younger ages (114). Socioeconomics, racial 
disparity, and treatment access may lead to differential treatment and 
mortality according to race (115). In addition, research has begun to 
suggest that race and ethnic differences play a role in the metabolism of 
several medications, including anti-hypertensives (116).  
 Income level: this variable is used to represent the socio-economic 
status of the subjects which might confound the results and thus needs to be 
adjusted for. This variable is divided into 8 different categories as shown in 
table 3.2 below: 
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Table 3.2: Eight levels of the income level variable 
 
 
 
 
 
 
 
 
 
 
 Time dependent covariates, the variables that may change in value over 
the course of the observation, including: 
 ACEI/ ARB use at baseline and throughout the duration of the 
study: We are interested in investigating the effect of the use of 
ACEI/ARB on the outcome. The use of any of these medications 
might change from one year to another which necessitates the 
inclusion of this variable in a time dependent manner.  ACEI/ARB 
users who also used other anti-hypertensives concomitantly were 
also considered in the ACE/ARB exposed group. Individuals who 
used anti-hypertensives other than ACEI/ARB were considered not 
exposed to ACEI/ARB for that observation period. 
Value Income level 
1 Under $5,000 
2 $ 5,000 to $7,999 
3 $8,000 to $11,999 
4 $12,000 to $15,999 
5 $16,000 to $24,999 
6 $25,000 to $34,999 
7 $35,000 to $49,999 
8 Over $50,000 
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 SBP at baseline and throughout the duration of the study: The high 
blood pressure is a known significant predictor of CVD. This 
variable was measured at baseline and then every follow-up until 
year 11 except for year 8. SBP was not collected in year 8. It was 
estimated by using year 7 readings. 
 Total number of antihypertensive medications used: This variable 
might represent another indicator for the control of high blood 
pressure in the subjects. It was calculated at baseline and each 
follow-up year. The anti-hypertensives included the use of any beta 
blocker, any vasodilator, any ACEI, any ARB, any alpha blocker, 
any calcium channel blocker alone or combined with a diuretic in 
the same pill, plus, the use of any thiazide, loop diuretic, potassium 
sparing diuretic as single agents in the antihypertensive pill. 
 Development of diabetes and CHF throughout the study: 
Hypertensive diabetic subjects and subjects who develop CHF in 
any of the follow-up years would have been prescribed ACEI/ARB 
according to established clinical guidelines. Therefore, the 
development of diabetes or CHF could confound the effect of 
ACEI/ARB on the cardiovascular outcome and a confounding by 
indication bias can be adjusted for by including these variables as 
time dependent variables.  
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At baseline, year 4, year 5 and year 9, fasting glucose levels 
were collected and diabetes was defined according to the ADA 
criteria (fasting glucose level higher than or equal to 126 mg/dl) or 
if they were on anti-diabetic medications. At baseline, oral glucose 
tolerance test data were available; therefore, 2-hour plasma glucose 
level higher than 200 mg/dl was also used to define diabetes at 
baseline. In years other than baseline, year 4, year 5, or 9, diabetes 
diagnosis was solely based on the use of anti-diabetic medications 
due to the fact that fasting labs and oral glucose tolerance tests were 
not performed at every follow-up year. We analyzed development 
of diabetes starting from baseline until year 11. 
Starting from year 12, there were no reliable measurements of 
SBP, and fasting plasma glucose. In addition, the data for the 
development of diabetes and CHF were retrieved from patients’ 
telephone self report with no validation from medical records. 
Therefore, in the analysis, the event follow-up data were limited to 
the first 11 years of the study. 
Endpoint:  
The primary endpoint was defined as the occurrence of any first incident CVD: 
MI, claudication, stroke, TIA, angina, angioplasty, CABG, ECG MI (silent MI) or death 
due to CHD. The incidence of each of these events was studied separately as secondary 
endpoints. The effects of ACEI/ARB on the incidence of cerebrovascular events and 
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CHD events were investigated separately. Cerebrovascular accident was defined as 
development of stroke or TIA. CHD included MI, angina, ECG MI and death due to 
coronary disease. 
Statistical Analysis 
 
A Cox hazards model with time dependent covariates was used to analyze the 
risk of developing cardiovascular events in users of ACE/ARB compared to non-users, 
adjusting for confounding and possible significant interactions. ACEI/ARB use, SBP, 
development of diabetes, number of antihypertensive medications and development of 
CHF were treated as time dependent annual observations. Subjects were censored if 
they did not develop any cardiovascular event during the follow-up period or if they did 
not make follow-up visits. Hazard ratios and their associated 95 % confidence intervals 
were calculated as the exponentiation of coefficients from the Cox model. In general a 
p-value ≤ 0.05 was considered as statistically significant unless stated otherwise. 
Model Building Technique 
 
The Cox regression analysis was performed for the use of ACEI/ARB 
(unadjusted model) and for each potential covariate separately in univariate analyses. 
Potential covariates that were of clinical interest (determined apriori) or those that 
reached a liberal significance level of 0.25 were kept. All these variables were included 
in the multivariable model. When adding each term, any variable that lost its 
significance were removed while checking that the model without the additional term 
did not result in a poorer fit by comparing the -2 log likelihood between the models. A 
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difference in the -2 log likelihood greater than 3.84 for 1 degree of freedom was 
considered as statistically significant. If the coefficients of the reduced model changed 
by more than 20% after elimination of a term, then the excluded variable may have been 
an important confounder and that term was included back to the model. Additionally, 
any discarded variable at the univariate stage was added to the multivariable model to 
evaluate again if addition of these eliminated variables improved the model 
significantly by comparing the -2 log likelihood and assessing the percent change in the 
coefficients in the model. The scale of the continuous variables in the model was 
checked for linearity as well. Clinically plausible interactions were included, including 
interactions between ACEI/ARB and age, ACEI/ARB and gender, and ACEI/ARB and 
race. We also assessed the proportional hazard assumption and the goodness of fit of the 
multivariable model. 
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Definition of the Metabolic Syndrome in the 4 Different Studies 
 
Study number 1: The metabolic syndrome was defined based on the WHO criteria. 
Study number 2: The metabolic syndrome was defined based on the EGIR criteria. 
Study number 3: The metabolic syndrome was defined based on the ATP criteria. 
Study number 4: The metabolic syndrome was defined based on the AACE criteria. 
 
The IDF criteria for the metabolic syndrome may not be valid for the diagnosis 
of the metabolic syndrome in the elderly (117-119); therefore, it was not considered in 
our analysis as the dataset contained only elderly subjects. The IDF criteria included 
obesity as an obligatory parameter in the metabolic syndrome. This means that if a 
subject showed an increase of all the parameters involved in the diagnosis of the 
metabolic syndrome but had a waist circumference in the normal range, that subject 
would not be defined as a metabolic syndrome patient although he/she was at high risk 
for CVD. The IDF cutoff points especially for the waist circumference were lower than 
the other criteria resulting in the inappropriateness of the use of these criteria in the 
elderly (high waist circumference for men according to the IDF is defined as a waist 
circumference > 94 cm while other criteria defines high waist circumference if greater 
than 102 cm). Some studies found that IDF-metabolic syndrome patients constituted 
about half of the general population; thus it should be considered as a “normal variant” 
(120). 
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Specific Aim 2 
 
Identify the effect of ACEI /ARB on the long term development of cardiovascular 
events in elderly non-diabetic hypertensive patients with insulin resistance. 
Rationale 
 
It has been suggested that making the diagnosis of the metabolic syndrome 
based on specific number of risk factors, as shown in the definitions of metabolic 
syndrome above, might not be a sensitive measure of insulin resistance (121). One of 
the most commonly used surrogate measures of insulin resistance in epidemiological 
research is the HOMA-IR derived from the product of fasting insulin and fasting 
glucose. Individuals with HOMA-IR values above 75th percentile of the study 
population are usually considered insulin resistant (11). We expect that elderly 
hypertensive patients with evidence of insulin resistance who were prescribed ACEI or 
ARB to have a lower incidence of cardiovascular events when compared to the control 
group who were prescribed other anti-hypertensives. 
Design 
 
This study was a retrospective cohort study that utilized the CHS database. The 
subjects included in the analysis were non-diabetic and had been prescribed 
antihypertensive medication at baseline or during any of the follow-up years. In 
addition, these subjects had evidence of insulin resistance. Insulin resistance was 
defined by being in the upper quartile of the HOMA level of the study population. The 
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exposed group was identified based on their exposure to ACEI or ARB, and the control 
group consisted of individuals who used anti-hypertensives other than ACEI or ARB. 
The incidence rate for the primary and secondary endpoints was compared between the 
exposed and the non-exposed groups adjusting for the possible confounding factors. 
Data Source 
 
The data source for Specific Aim 2 was the same as Specific Aim 1. 
Inclusion /Exclusion Criteria, Covariates and Endpoint Definition 
 
The inclusion and exclusion criteria for Specific Aim 2 were as follows: 
Inclusion Criteria: 
 Evidence of insulin resistance by being in the upper quartile of the 
HOMA level for non-obese, non-diabetic subjects in the cohort. 
 Subjects who had used any antihypertensive medication during any of 
the follow-up years. 
Exclusion criteria, covariates and endpoint for Aim 2 were the same as Aim 1. 
Statistical Analysis 
The statistical analyses employed for aim 2 were the same as aim 1. 
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Chapter IV  
Results 
Introduction 
 
This chapter begins with a presentation of descriptive statistics followed by the 
results of each specific aim. 
Of the original 5888 subjects enrolled in the CHS dataset, the numbers of 
subjects who met the inclusion criteria are: 990, 749, 777, and 1102 respectively for 
study 1-4 of the first specific aim. On the other hand, 1216 subjects satisfied the 
inclusion/ exclusion criteria for specific aim 2. Table 4.1 below shows the sample size, 
entry and follow-up time data for both specific aims. 
 
Table 4.1: Sample size, entry and follow-up time, number of events for both specific aims 
 
Study # subjects Entry time (days) 
Follow-up time (days) 
# of events 
minimum maximum median 
Specific aim 1 
WHO 990 0 12 4035 3361.5 339 
EGIR 749 0 28 4035 3602 248 
ATP 777 0 20 4035 3484 254 
AACE 1102 0 20 4035 3489 368 
Specific aim 2 
Upper quartile  
Of HOMA 
1216 0 28 4035 3683 402 
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Cohort Characteristics 
Specific Aim 1 
Study Number 1: The metabolic syndrome was defined based on the WHO 
criteria 
A) The Use of Angiotensin Converting Enzyme Inhibitors and/or 
Angiotensin Receptor Blockers 
 
At entry into the study, 109 out of the 990 subjects (11%) were taking ACEI. 
None of the subjects at entry used ARBs. The use of ACEI/ARB increased from 
baseline until year 11 where 27.3 % used ACEI and/ or ARB as shown in figure 4.1 
below. The average duration of use of ACEI/ARB was 2.1 years. 
 
Figure 4.1: Percentage of use of ACEI and/or ARB over the follow-up years using 
the WHO definition for the metabolic syndrome 
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B) Baseline Characteristics of Subjects 
 
Baseline characteristics of subjects were compared between the exposed group 
(exposed to ACEI/ARB) and the control group. At baseline, there were no statistically 
significant differences between the 2 groups regarding their age, gender, smoking 
habits, triglycerides, HDL, LDL levels, BMI, total number of antihypertensive 
medications used or fasting glucose level. However, the ACEI/ARB group contained a 
higher percentage of African Americans and had a higher SBP compared to the control 
group. The use of different antihypertensive medications (thiazides, loop diuretics, 
potassium sparing diuretics, calcium channel blockers, vasodilators as single agents) 
was similar between the 2 groups. However, the exposed group was prescribed less beta 
blockers and alpha blockers as presented in table 4.2 below. 
However, it should be taken into consideration that the subjects included in the 
exposed and the control groups changed consistently at each follow-up year. Therefore, 
these comparisons did not reflect the differences between the 2 groups at any other 
follow-up year. 
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Table 4.2: Baseline comparisons between the exposed and the control groups using the WHO 
definition for the metabolic syndrome 
 
Covariate  
ACEI/ARB  
users 
Control 
group 
p value 
Gender (% males) 47% 43% 0.41 
Smoking 
1=never  
2=former 
3=current 
1  40.4% 1  47.7% 
0.35 2  47.7% 2  41.5% 
3  11.9% 3  10.8% 
Black 23.85% 12.49% 0.0011 
Triglycerides (mg/dl) 142.7 150.6 0.2091 
HDL (mg/dl) 51.9 51.8 0.91 
LDL (mg/dl) 130.6 133.3 0.45 
Age 72.1 72.98 0.104 
BMI 27.8 27.9 0.84 
# HTN medications among  
hypertensive subjects 
1.80 1.71 0.28 
SBP 145.9 141.7 0.047 
Fasting glucose (mg/dl) 103.4 102.8 0.45 
Drug use at baseline 
Beta blockers  8.26% 18.84% 0.0063 
Thiazides  12.84% 18.84% 0.125 
Loop diuretics 7.34% 5.56% 0.45 
K sparing diuretic 0.00% 1.59% 0.185 
Calcium channel blocker 17.40% 11.12% 0.054 
Vasodilators 12.84% 10.67% 0.49 
Alpha blockers 0.00% 4.54% 0.023 
Angiotensin receptor 
blockers 
0.00% 0.00%   
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C) Characteristics of Subjects throughout the Study 
 
The percent of hypertensive subjects with uncontrolled blood pressure was 
compared between the exposed and the control groups at baseline and each follow-up 
year as shown in table 4.3 below. We noticed that in the 11 years of follow-up, the 
percentage of subjects with uncontrolled blood pressure was not significantly different 
between those who used ACE/ARB and those who did not use any of these 2 classes of 
drugs. These blood pressure data suggested that any difference in incident 
cardiovascular events between the two groups during the follow-up period would not 
probably be due to a difference in blood pressure control. 
 
Table 4.3: Percentage of hypertensive subjects with uncontrolled blood pressure (>140/90) in both 
the exposed and the control groups using the WHO definition for the metabolic syndrome 
 
 
 
 
 
 
 
 
 
 
Covariate 
ACEI/ARB 
users (%) 
Control  
group (%) 
p value 
Baseline 58.7  60.3  0.75 
Year 1 94.12  92.98  0.728 
Year 2 89.71  92.4  0.4398 
Year 3 47.62  52.89  0.274 
Year 4 52.9  54.57  0.718 
Year 5 54.55  59.38  0.2718 
Year 6 52.9  59.48  0.135 
Year 7 52.44  58.57  0.155 
Year 8 55.38  59.57  0.3011 
Year 9 60  65.32  0.175 
Year 10 51.29  55.11  0.328 
Year 11 59.91 63.01  0.42 
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As noted previously, there might be a possible bias due to the recommended 
prescribing of ACEI/ARB for CHF patients that might confound the results. The 
percentage of subjects with CHF in both the exposed and control groups over the 11 
years of follow-up are shown in table 4.4 below. It appears that those prescribed 
ACEI/ARB were more likely to have CHF. Using Cox regression model, where the 
outcome of interest was defined as the time to develop CHF, we observed that there was 
no statistically significant difference between those exposed to ACEI/ARB and the 
control group in terms of incident CHF that developed during the study as shown in 
table 4.5 below. However, this did not eliminate the possibility of prevalent CHF that 
would have led to the use of ACEI/ARB, as suggested by data in table 4.4. CHF as a 
time dependent covariate was therefore included in the multivariable model.  
 
Table 4.4: Percentage of subjects with CHF at baseline and each follow-up year in both the exposed 
and the control groups using the WHO definition for the metabolic syndrome 
 
Covariate 
ACEI/ARB  
users (%) 
Control group 
(%) 
p value 
Baseline 0  0  - 
Year 1 0  1.36  0.38 
Year 2 0.93  1.25  1.00 
Year 3 1.85  2.72  0.00019 
Year 4 9.45  2.2  0.031 
Year 5 10.07  5.17  0.0308 
Year 6 12.74  6.36  0.0076 
Year 7 13.04  8.2  0.0691 
Year 8 15.91  9.58  0.0214 
Year 9 21.15  10.61 0.00016 
Year 10 24.89  11.37  < 0.0001 
Year 11 23.14  12.52  < 0.0001 
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Table 4.5: Cox regression model results for the effect of the use of ACEI/ARB on the time to 
develop CHF using the WHO definition for the metabolic syndrome 
 
 
Similarly, there was a possible confounding by indication bias for ACEI/ARB in 
diabetic patients. The percentage of subjects who developed diabetes in both the 
exposed and the control groups over the 11 years of follow-up were similar for the most 
part as shown in table 4.6. Cox regression analysis showed that the time to develop 
diabetes for the most part was not different between those who used ACEI/ARB and the 
control groups, as shown in table 4.7 below. These data suggested that any difference in 
incident cardiovascular events between the two groups during the follow-up period 
would not probably be due to a difference in the development of diabetes during the 
study. 
Analysis of Maximum Likelihood Estimates 
Variable DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio (HR) 
95% HR  
Confidence 
Limits 
Use of ACEI 
And/or  
ARB 
1 0.11381 0.21261 0.2865 0.5925 1.121 0.74 1.70 
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Table 4.6: Percentage of subjects diagnosed with diabetes at each follow-up year in both the 
exposed and the control groups using the WHO definition for the metabolic syndrome 
 
 
Table 4.7: Cox regression model results for the effect of the use of ACEI and/or ARB on the time to 
develop type 2 diabetes using the WHO definition for the metabolic syndrome 
 
Study number 2: The metabolic syndrome was defined based on the EGIR 
criteria 
A) The Use of Angiotensin Converting Enzyme Inhibitors and/or 
Angiotensin Receptor Blockers 
 
At entry into the study, 75 out of the 749 subjects (10.01%) were taking ACEI 
and none of the subjects at entry used ARB. The use of ACEI/ARB increased from 
baseline until year11 where 24.7 % used ACEI and/ or ARB as shown in figure 4.2 
below. The average duration of use of ACEI and/ or ARB was 1.9 years. 
Diabetes diagnosis 
ACEI/ARB 
 users (%) 
Control  
group (%) 
p value 
Baseline 0  0  - 
Year 1 0.93  0.11  0.2064 
Year 2 0.93  0.23  0.2931 
Year 3 1.57  0.35  0.1258 
Year 4 1.44  1.18  0.6803 
Year 5  5.1  2.52  0.1149 
Year 6 3.11  0.84  0.0321 
Year 7 3.98  1.47 0.0605 
Year 8 5.29 1.79 0.01 
Year 9 6.22 4.44 0.2898 
Year 10 4.71 2.72 0.1486 
Year 11 5.56 3.19 0.0951 
Analysis of Maximum Likelihood Estimates 
Variable DF Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio 
(HR) 
95% HR  
Confidence 
Limits 
Use of ACEI 
and/or  
ARB 
1 0.17022 0.37839 0.2024 0.6528 1.186 0.57 2.489 
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Figure 4.2: Percentage of use of ACEI and/or ARB over the follow-up years using 
the EGIR definition for the metabolic syndrome 
 
 
B) Baseline Characteristics of Subjects 
 
The baseline characteristics of subjects were compared between those exposed 
to ACEI and/or ARB and the control group. At baseline, there were no significant 
differences between the 2 groups regarding their gender, age, smoking habits, 
triglycerides, HDL, LDL levels, BMI, total number of antihypertensive medications 
used, and fasting glucose level. On the other hand, the exposed group contained a 
higher percentage of African Americans and they had higher SBP at baseline. The use 
of different antihypertensive medications (beta blockers, thiazide diuretics, loop 
diuretics, potassium sparing diuretics, vasodilators, alpha blockers) was similar between 
the 2 groups. However, the exposed group was prescribed more calcium channel 
blockers compared to the control group as shown in table 4.8 below. 
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However, it should be taken into consideration that the subjects included in the 
exposed and the control groups changed significantly at each follow-up year. Therefore, 
these baseline comparisons do not reflect the differences between the exposed and the 
control groups at any other follow-up time. 
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Table 4.8: Baseline comparisons between the exposed and the control groups using the EGIR 
definition for the metabolic syndrome 
 
Covariate 
ACEI/ARB  
users 
Control 
group 
p value 
Gender (% males) 42.6 40.36 0.699 
Smoking 
1=never 
2=former 
3=current 
38.7 50.3 
0.078 52.00 38.58 
9.33 11.13 
Black 30.67 13.65 0.0001 
Triglycerides (mg/dl) 138.87 142.70 0.5893 
HDL (mg/dl) 50.5 52.5 0.2506 
LDL (mg/dl) 130.95 133.70 0.5091 
Age 72.1 72.4 0.6516 
BMI 28.07 27.60 0.3462 
# HTN medications  
 among hypertensive subjects
1.77 1.72 0.59 
SBP 143.9 138.4 0.023 
Fasting glucose (mg/dl) 101.3 99.9 0.1877 
Drug use at baseline 
Beta blockers  9.33 13.65 0.2951 
Thiazides 13.33 16.91 0.4287 
Loop diuretics 6.67 4.01 0.2798 
K sparing diuretic 0.00 1.78 0.244 
Calcium channel blocker 21.33 10.09 0.0034 
Vasodilators 12.00 8.01 0.2378 
Alpha blockers 0.00 3.26 0.1123 
Angiotensin receptor 
 blocker 
0.00 0.00  
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C) Characteristics of Subjects throughout the Study 
 
The percent of hypertensive subjects with uncontrolled blood pressure was 
compared between the exposed and the control groups at baseline and each follow-up 
year as shown in table 4.9 below. We notice that in the 11 years of follow up, the 
percentage of subjects with uncontrolled blood pressure was not significantly different 
between those who used ACEI/ARB and those who did not use any of these 2 classes of 
drugs. These blood pressure data suggest that any difference in incident cardiovascular 
events between the two groups during the follow-up period would probably not be due 
to a difference in blood pressure control. 
 
Table 4.9: Percentage of hypertensive subjects with uncontrolled blood pressure (>140/90) in both 
the exposed and the control groups using the EGIR definition for the metabolic syndrome 
 
 
 
 
 
 
 
 
 
 
 
Covariate 
ACEI/ARB 
users (%) 
Control  
group (%) 
p value 
Baseline 57.33 58.88 0.7991 
Year 1 91.30 91.35 0.9909 
Year 2 84.78 89.63 0.3228 
Year 3 48.84 56.19 0.2061 
Year 4 55.10 57.83 0.6190 
Year 5 57.84 60.67 0.5966 
Year 6 58.18 61.72 0.4937 
Year 7 53.10 59.91 0.1871 
Year 8 55.56 60.74 0.2841 
Year 9 61.36 62.82 0.7626 
Year 10 54.19 54.68 0.9176 
Year 11 61.84 61.03 0.8609 
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The percentage of subjects with CHF in both the exposed and the control group 
over the 11 years of follow-up are shown in table 4.10 below. It appears that subjects 
prescribed ACEI/ARB were more likely to have CHF. Cox regression model, where the 
outcome of interest was defined as the time to develop CHF, showed statistically 
significant difference between those exposed to ACEI/ARB and the control groups in 
terms of incident CHF as shown in table 4.11 below. Subjects who were exposed to 
ACEI/ARB had higher risk to develop CHF, suggesting that subjects at risk for CHF 
could have been prescribed more ACEI/ARB. Thus, development of CHF needs to be 
adjusted for in our analysis. 
 
Table 4.10: Percentage of subjects with CHF at baseline and each follow-up year in both the 
exposed and the control groups using the EGIR definition for the metabolic syndrome 
 
 
Development of CHF 
ACEI/ARB  
users (%) 
Control  
group (%) 
p value 
Baseline 0 0 - 
Year 1 0 1.04 1.00 
Year 2 1.37 0.89 0.5137 
Year 3 1.37 2.2 1.00 
Year 4 8.05 1.66 0.0025 
Year 5 12.12 4.0 0.0021 
Year 6 16.19 4.97 0.000124 
Year 7 14.78 6.15 0.0031 
Year 8 16.39 7.66 0.005 
Year 9 21.68 8.75 < 0.0001 
Year 10 23.38 9.41 < 0.0001 
Year 11 21.14 10.45 0.00046 
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Table 4.11: Cox regression model results for the effect of the use of ACEI and/or ARB on the time 
to develop CHF using the EGIR definition for the metabolic syndrome 
 
 
 
 
 
The percentage of subjects who developed diabetes over the 11 years of follow-
up in both the exposed and the control groups are presented in table 4.12 below. The 
percentage of subjects with diabetes was not significantly different between subjects 
who used ACEI/ARB and those who did not used any of these 2 classes of drugs except 
for 2 years (year 5 and year 8). The Cox model showed that the time to develop diabetes 
was not significantly different between those who used ACEI/ARB and the control 
group, as shown in table 4.13 below. However, this did not eliminate the possibility that 
developing diabetes during the study would have led to the use of ACEI/ARB, as 
suggested by data in table 4.12. Development of diabetes as a time dependent covariate 
was therefore included in the multivariate model. 
Analysis of Maximum Likelihood Estimates 
Variable DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio  
(HR) 
95% HR  
Confidence 
Limits 
Use of ACEI 
and/or  
ARB 
1 0.50496 0.25022 4.0727 0.0436 1.657 1.02 2.71 
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Table 4.12: Percentage of subjects diagnosed with diabetes at each follow-up year in both the 
exposed and the control groups using the EGIR definition for the metabolic syndrome 
 
 
Table 4.13: Cox regression model results for the effect of the use of ACEI and/or ARB on the time 
to develop type 2 diabetes using the EGIR definition for the metabolic syndrome 
 
Diabetes  
diagnosis 
ACEI/ARB  
users (%) 
Control  
group (%) 
p value 
Baseline 0 0 - 
Year 1 1.37 0.15 0.1855 
Year 2 1.37 0.15 0.1855 
Year 3 1.15 0.45 0.3904 
Year 4 1.01 1.08 1.00 
Year 5 4.76 1.55 0.0463 
Year 6 2.61 0.79 0.1102 
Year 7 3.28 1.12 0.0877 
Year 8 4.20 0.99 0.0147 
Year 9 4.55 2.69 0.2906 
Year 10 4.57 1.92 0.0583 
Year 11 4.32 2.30 0.1957 
Analysis of Maximum Likelihood Estimates 
Variable DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio 
(HR) 
95% HR  
Confidence 
Limits 
Use of ACEI 
and/or  
ARB 
1 -0.10049 0.60553 0.0275 0.8682 0.904 0.28 2.96 
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Study number 3: The metabolic syndrome was defined based on the ATP 
criteria 
A) The Use of Angiotensin Converting Enzyme Inhibitors and/or 
Angiotensin Receptor Blockers 
 
At baseline, 72 out of the 777 subjects (9.3%) were taking ACEI and none of the 
subjects at entry used ARB. The use of ACEI/ARB increased from baseline until year11 
where 26.1 % used ACEI and/ or ARB as shown in figure 4.3 below. The average 
duration of use of ACEI/ARB was 1.9 years. 
 
Figure 4.3: Percentage of use of ACEI and/or ARB over the follow-up years using 
the ATP definition for the metabolic syndrome 
 
 
0
5
10
15
20
25
30
0 5 10 15 20
years
%
 o
f 
u
se
 o
f 
an
g
io
te
n
si
n
 c
o
n
ve
rt
in
g
 
en
zy
m
e 
in
h
ib
it
o
rs
 o
r 
an
g
io
te
n
si
n
 
re
ce
p
to
r 
b
lo
ck
er
s
  57
B) Baseline Characteristics of Subjects 
 
Baseline characteristics of subjects were compared between those exposed to 
ACEI and/ or ARB and the control group. At baseline, there were no statistically 
significant differences between the 2 groups regarding their age, gender, smoking 
habits, triglycerides, HDL, LDL levels, BMI, total number of blood pressure 
medications used, fasting glucose or SBP. However, the exposed group contained a 
higher percentage of African Americans. The use of the different antihypertensive 
medications (thiazide diuretics, potassium sparing diuretics, vasodilators and alpha 
blockers) was similar between the 2 groups. However, the exposed group was 
prescribed significantly less beta blockers but more loop diuretics and calcium channel 
blockers compared to the control group as shown in table 4.14 below. 
However, it should be taken into consideration that the subjects included in the 
exposed and the control groups changed consistently at each follow-up year. Therefore, 
these baseline comparisons did not represent the differences between the exposed and 
the control groups at any other follow-up year. 
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Table 4.14: Baseline comparisons between the exposed and the control groups using the ATP 
definition for the metabolic syndrome 
 
Covariate 
ACEI/ARB  
users (%) 
Control 
group (%) 
p value 
Gender (% males) 42 33 0.1214 
Smoking 
1=never 
2=former 
3=current 
1  40 1  51 
0.1937 2  47 2  37 
3  13 3  12 
Black 21 11 0.015 
Triglycerides (mg/dl) 165.4 160.2 0.5 
HDL (mg/dl) 47.6 49 0.38 
LDL (mg/dl) 130.0 136.2 0.15 
Age 71.8 72.5 0.29 
BMI 28.7 28.6 0.9 
# HTN medications  
among hypertensive subjects 
1.85 1.70 0.207 
SBP 143.8 140.0 0.2 
Fasting glucose (mg/dl) 105.3 104.4 0.37 
 Drug use at baseline 
Beta blockers  5.56% 18.70% 0.0051 
Thiazides 9.7% 16.7% 0.122 
Loop diuretics 11.1% 4.4% 0.0129 
K sparing diuretic 0.0% 1.4% 0.31 
Calcium channel blocker 18.1% 8.7% 0.0096 
Vasodilators 13.9% 9.4% 0.22 
Alpha blockers 0.00% 3.97% 0.09 
Angiotensin receptor  
blocker 
0.00% 0.00%  
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C) Characteristics of Subjects throughout the Study 
 
The percent of hypertensive subjects with uncontrolled blood pressure was 
compared between the exposed and the control groups at baseline and each follow-up 
year as shown in table 4.15 below. We noticed that in the 11 years of follow-up, the 
percentage of subjects with uncontrolled blood pressure was not significantly different 
between those who used ACEI/ARB and those who did not use any of these 2 classes of 
drugs except for year 3. In year 3, higher percentage of hypertensive subjects had 
uncontrolled blood pressure in the control group. To account for any possible difference 
in the control of blood pressure between the exposed and the control groups, SBP and 
the “total number of anti-hypertensives used” were included in the model as time 
dependent variables. 
 
Table 4.15: Percentage of hypertensive subjects with uncontrolled blood pressure (> 140/90) in both 
the exposed and the control groups using the ATP definition for the metabolic syndrome 
 
 
 
 
 
 
 
 
 
Covariate 
ACEI/ARB 
users (%) 
Control  
group (%) 
p value 
Baseline 57 62 0.37 
Year 1 96 93 0.51 
Year 2 89 92 0.38 
Year 3 38 55 0.0038 
Year 4 47 56 0.098 
Year 5 55 59 0.43 
Year 6 50 60 0.052 
Year 7 51 60 0.074 
Year 8 53 61 0.088 
Year 9 57 64 0.082 
Year 10 50 56 0.18 
Year 11 58 62 0.43 
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The percentage of subjects with CHF in both the exposed and control group over 
the 11 years of follow-up are shown in table 4.16 below, suggesting that there was a 
difference between groups in some years. It appears that those prescribed ACEI/ARB 
were more likely to have CHF. Cox regression model, where the outcome of interest 
was defined as the time to develop CHF, showed no statistically significant difference 
between the exposed and the control groups in terms of incident CHF that developed 
during the study as shown in table 4.17 below. However, this did not eliminate the 
possibility of prevalent CHF that would have led to the use of ACEI/ARB, as suggested 
by data in table 4.16. CHF as a time dependent variable was therefore included in the 
multivariable model. 
 
Table 4.16: Percentage of subjects with CHF at baseline and each follow-up year in both the 
exposed and the control groups using the ATP definition for the metabolic syndrome 
 
Development of CHF 
ACEI/ARB 
 users (%) 
Control  
group (%) 
p value 
Baseline 0 0 - 
Year 1 0% 1.42% 0.611 
Year 2 0% 1.42% 0.611 
Year 3 0% 2.27% 0.3857 
Year 4 2.6% 2.29 0.6966 
Year 5 6.06% 4.72% 0.6152 
Years 6 10.43% 5.44% 0.0559 
Year 7 12.07% 6.66% 0.0535 
Year 8 13.08% 8.8% 0.1406 
Year 9 19.61% 9.3% 0.00089 
Year 10 21.05% 11.06% 0.0013 
Year 11 21.08% 11.99% 0.0035 
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Table 4.17: Cox regression model results for the effect of the use of ACEI and/ or ARB on the time 
to develop CHF using the ATP definition for the metabolic syndrome 
 
 
Similarly, the percentage of subjects who developed diabetes over the 11 years 
of follow-up in both the exposed and the control group are shown in table 4.18 below. 
Cox model showed that the time to develop diabetes was not different between those 
who used ACEI/ARB and the control group, as shown in table 4.19 below. Thus any 
difference in incident cardiovascular events between the two groups during the follow-
up period would not probably be due to a difference in the development of diabetes. 
 
Table 4.18: Percentage of subjects diagnosed with diabetes at each follow-up year in both the 
exposed and the control groups using the ATP definition for the metabolic syndrome 
 
Analysis of Maximum Likelihood Estimates 
Variable DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio (HR) 
95% HR  
Confidence 
Limits 
Use of ACEI 
and/or  
ARB 
1 0.03200 0.26446 0.0146 0.9037 1.033 0.615 1.7 
Diabetes  
diagnosis 
ACEI/ARB  
users (%) 
Control  
group (%) 
p value 
Baseline 0 0 - 
Year 1 0 0.14 1.00 
Year 2 0 0.14 1.00 
Year 3 1.3 0.29 0.2691 
Year 4 1.01 1.18 1.00 
Year 5 6.09 3.02 0.1017 
Year 6 2.59 0.76 0.103 
Year 7 4.62 1.24 0.0184 
Year 8 4.58 1.76 0.064 
Year 9 7.02 4.95 0.3369 
Year 10 4.86 2.87 0.2387 
Year 11 5.91 3.48 0.1506 
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Table 4.19: Cox regression model results for the effect of the use of ACEI and/ or ARB on the time 
to develop type 2 diabetes using the ATP definition for the metabolic syndrome 
 
 
Study number 4: The metabolic syndrome was defined based on the AACE 
criteria 
A) The Use of Angiotensin Converting Enzyme Inhibitors and/or 
Angiotensin Receptor Blockers 
 
At entry into the study, 95 out of the 1102 subjects (8.6 %) were taking ACEI 
and none of the subjects at entry used ARB. The use of ACEI/ARB increased from 
baseline until year 11 where 23.96 % used ACEI and/ or ARB as shown in figure 4.4 
below. The average duration of use of ACEI/ARB was equal to 1.8 years. 
Analysis of Maximum Likelihood Estimates 
Variable DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio 
(HR) 
95% HR  
Confidence  
Limits 
Use of ACEI 
and/or  
ARB 
1 0.18609 0.43251 0.1851 0.6670 1.205 0.516 2.812 
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Figure 4.4: Percentage of use of ACEI and/or ARB over the follow-up years using 
the AACE definition for the metabolic syndrome  
 
 
B) Baseline Characteristics of Subjects 
 
Baseline characteristics of subjects were compared between those exposed to 
ACEI and/or ARB and the control group. At baseline, there were no statistically 
significant differences between the 2 groups regarding their age, smoking habits, 
triglycerides, HDL, LDL levels, BMI, the total number of antihypertensive medications 
used and fasting plasma glucose. However, the exposed group had higher percentage of 
males and African Americans and they had higher SBP. The use of different 
antihypertensive medications (thiazide diuretics, potassium sparing diuretics, calcium 
channel blockers, vasodilators and alpha blockers) were similar between the 2 groups. 
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However, the exposed group was prescribed significantly less beta blockers but more 
loop diuretics compared to the control group as shown in table 4.20 below. 
However, it should be taken into consideration that the subjects included in the 
exposed and the control groups changed consistently at each follow-up year. Therefore, 
these baseline comparisons did not reflect the differences between the 2 groups at any 
other follow-up year. 
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Table 4.20: Baseline comparisons between the exposed and the control groups using the AACE 
definition for the metabolic syndrome 
 
Covariate 
ACEI/ARB  
users 
Control  
group 
p value 
Gender (% males) 51.58 41.1 0.048 
Smoking 
1=never 
2=former 
3=current 
40.00 49.06 
0.2327 46.32 40.02 
13.68 10.92 
Black 17.89 10.43 0.0266 
Triglycerides (mg/dl) 142.5 145.7 0.6059 
HDL (mg/dl) 50.37 52.18 0.2296 
LDL (mg/dl) 130.45 134.40 0.2809 
Age 72.63 72.70 0.8689 
BMI 27.6 27.7 0.8158 
# HTN medications  
 among hypertensive subjects 
1.78 1.72 0.5255 
SBP 145.295 139.497 0.0078 
Fasting glucose (mg/dl) 104.4 102.65 0.0771 
Drug use at baseline 
Beta blockers  5.26 15.49 0.007 
Thiazides 15.79 16.58 0.842 
Loop diuretics 9.47 4.47 0.0308 
K sparing diuretic 0.00 0.89 0.3548 
Calcium channel blocker 13.68 9.04 0.1386 
Vasodilators 11.58 8.64 0.336 
Alpha blockers 0.00 3.57 0.061 
Angiotensin receptor  
blockers 
0.00 0.00  
  66
C) Characteristics of Subjects throughout the Study 
 
The percent of hypertensive subjects with uncontrolled blood pressure was 
compared between the exposed and the control groups at baseline and each follow-up 
year as shown in table 4.21 below. In year 3, 6, 7, 8, 9 and 10, the p value was less than 
0.05. In these years, the percentage of subjects with uncontrolled blood pressure was 
higher in the control group compared to the group who were prescribed ACEI/ARB. We 
adjusted for the control of blood pressure in our analyses by including the SBP and the 
total number of anti-hypertensives used as time dependent variables in the statistical 
models. 
 
Table 4.21: Percentage of hypertensive subjects with uncontrolled blood pressure (>140/90) in both 
the exposed and the control groups using the AACE definition for the metabolic syndrome 
 
 
 
 
 
 
 
 
 
The percentage of subjects with CHF in both the exposed and the control groups 
over the 11 years of follow-up are shown in table 4.22 below. It appears that those 
Covariate 
ACEI/ARB 
users (%) 
Control  
group (%) 
p value 
Baseline 56.84 62.14 0.316 
Year 1 94.83 93.91 0.7803 
Year 2 89.83 92.91 0.3921 
Year 3 44.44 55.84 0.0215 
Year 4 49.62 56.31 0.1541 
Year 5 52.35 60.71 0.0592 
Year 6 49.67 62.04 0.0048 
Year 7 48.50 59.39 0.0108 
Year 8 50.52 60.34 0.015 
Year 9 55.90 65.57 0.0142 
Year 10 48 57.4 0.0156 
Year 11 58.30 63.37 0.1853 
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prescribed ACEI/ARB were more likely to have CHF. Cox regression model where the 
outcome of interest was defined as the time to develop CHF showed no statistically 
significant difference between the exposed and the control groups in terms of incident 
CHF as shown in table 4.23. However, this did not eliminate the possibility of prevalent 
CHF that would have led to the use of ACEI/ARB, as suggested by data in table 4.22. 
CHF as a time dependent covariate was therefore included in the multivariate model. 
 
Table 4.22: Percentage of subjects with CHF at baseline and each follow-up year in both the 
exposed and the control groups using the AACE definition for the metabolic syndrome 
 
Development  
of CHF 
ACEI/ARB 
users (%) 
Control 
group (%)p 
p value 
Baseline  0 0 - 
Year 1 0 1.09 0.613 
Year 2 0 1.09 0.613 
Year 3 1.05 2.58 0.723 
Year 4 5.93 2.54 0.072 
Year 5 6.72 5.27 0.54 
Year 6 11.26 5.99 0.0223 
Year 7 12.58 7.64 0.044 
Year 8 16.76 9.1 0.0044 
Year 9 20.77 9.94 < 0.0001 
Year 10 23.77 10.69 < 0.0001 
Year 11 22.4 11.74 < 0.0001 
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Table 4.23: Cox regression model results for the effect of the use of ACEI and/or ARB on the time 
to develop CHF using the AACE definition for the metabolic syndrome 
 
 
The percentage of subjects who developed diabetes over the 11 years of follow-
up was for the most part similar in both the exposed and the control groups as presented 
in table 4.24 below. Cox regression model showed that the time to develop diabetes was 
not different between those who used ACEI/ARB and the control group, as shown in 
table 4.25 below. Thus any difference in incident cardiovascular events between the two 
groups during the follow-up period would not probably be due to a difference in the 
development of diabetes. 
 
Analysis of Maximum Likelihood Estimates 
Variable DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio (HR) 
95% HR  
Confidence 
Limits 
Use of ACEI 
and/or  
ARB 
1 0.09585 0.22221 0.1861 0.6662 1.101 0.71 1.701 
  69
Table 4.24: Percentage of subjects diagnosed with diabetes at each follow-up year in the exposed 
and the control groups using the AACE definition for the metabolic syndrome 
 
 
Table 4.25: Cox regression model results for the effect of the use of ACEI and/or ARB on the time 
to develop type 2 diabetes using the AACE definition for the metabolic syndrome 
 
 
Specific Aim 2 
A) The Use of Angiotensin Converting Enzyme Inhibitors and/or 
Angiotensin Receptor Blockers 
 
For the second specific aim, the study population consisted of elderly 
hypertensive non-diabetic subjects in the upper quartile of HOMA. The cut off point for 
Covariate 
ACEI/ARB  
users (%) 
Control  
group (%) 
p value 
Baseline 0 0 - 
Year 1 0 0.1 1.00 
Year 2 0 0.2 1.00 
Year 3 0.85 0.41 0.433 
Year 4 0.75 1.14 1.00 
Year 5 3.97 2.84 0.44 
Year 6 1.89 1.06 0.42 
Year 7 2.79 1.63 0.35 
Year 8 4.35 1.90 0.044 
Year 9 5.83 4.55 0.48 
Year 10 4 2.82 0.404 
Year 11 5.30 3.34 0.145 
Analysis of Maximum Likelihood Estimates 
Variable DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio 
(HR) 
95% HR  
Confidence Limits 
Use of ACEI 
and/or 
 ARB 
1 -0.03953 0.42628 0.0086 0.9261 0.961 0.42 2.22 
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the upper quartile of HOMA was found to be 2.52. Thus, a subject was considered to be 
insulin resistant if the HOMA was equal to or greater than 2.52.  
At entry into the study, 105 out of the 1216 subjects (8.63%) were taking ACEI 
and none of the subjects at entry used ARB. The use of ACEI/ARB increased from 
baseline until year 11 where 24.2 % used ACEI and/ or ARB as shown in figure 4.5 
below. The average duration of use of ACEI/ARB was equal to 1.7 years. 
Figure 4.5: Percentage of use of ACEI and/or ARB over the follow-up years for 
specific aim 2 
 
 
B) Baseline Characteristics of Subjects 
 
Baseline characteristics of subjects were compared between those exposed to 
ACEI and/or ARB and the control group. At baseline, there were no statistically 
significant differences between the 2 groups regarding their age, gender, smoking 
habits, triglycerides, HDL, LDL levels, BMI, total number of blood pressure 
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medications used, and fasting plasma glucose. However, the exposed group had a 
higher percentage of African Americans and higher SBP. The use of different 
antihypertensive medications (thiazide diuretics, potassium sparing diuretics, 
vasodilators and alpha blockers) was similar between the 2 groups. However, the 
exposed group was prescribed significantly more loop diuretics and calcium channel 
blockers as shown in table 4.26. 
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Table 4.26: Baseline comparisons between the exposed and the control groups for specific aim 2 
 
 
C) Characteristics of Subjects throughout the Study 
 
The percent of hypertensive subjects with uncontrolled blood pressure was 
compared between the exposed and the control groups at baseline and each follow-up 
Covariate 
ACEI/ARB  
users 
Control 
group p value 
Gender (% males) 43.81 39.69 0.41 
Smoking 
1=never 
2=former 
3=current 
39.05 48.51 
0.17 48.57 40.23 
12.38 11.25 
Black 22.86 12.06 0.0017 
Triglycerides (mg/dl) 142.3 141.8 0.9314 
HDL (mg/dl) 50.86 52.98 0.1434 
LDL (mg/dl) 132.6 134.7 0.5617 
Age 72.08 72.44 0.4725 
BMI 27.80 27.66 0.6804 
# HTN medications  
among hypertensive subjects
1.83 1.7 0.1193 
SBP 144.05 137.85 0.0024 
Fasting glucose (mg/dl) 103.4 102.2 0.1918 
Drug use at baseline 
Beta blockers  9.52 13.41 0.2587 
Thiazides 13.33 15.39 0.5746 
Loop diuretics 8.57 4.05 0.0316 
K sparing diuretic 0.00 1.17 0.2651 
Calcium channel blocker 20.00 7.65 <0.0001 
Vasodilators 12.38 7.47 0.0745 
Alpha blockers 0.00 2.88 0.078 
Angiotensin receptor  
blockers 
0.00 0.00  
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year as shown in table 4.27 below. The percentage of subjects with uncontrolled blood 
pressure was higher in the control group compared to the group who was prescribed 
ACEI/ARB in some of the follow-up years. We adjusted for the control of blood 
pressure in our analyses by including the SBP and the total number of anti-
hypertensives used as time dependent variables in the statistical models. 
 
Table 4.27: Percentage of hypertensive subjects with uncontrolled blood pressure (>140/90) in both 
the exposed and the control groups for specific aim 2 
 
 
 
 
 
 
 
 
 
The percentage of subjects with CHF in both the exposed and the control groups 
over 11 years of follow-up are shown in table 4.28 below. It appears that those 
prescribed ACEI/ARB were more likely to have CHF. Cox regression model, where the 
outcome of interest was defined as the time to develop CHF, showed no statistically 
significant difference between the exposed and the control groups in terms of incident 
CHF that developed during the study as shown in table 4.29. However, this did not 
eliminate the possibility of prevalent CHF that would have led to the use of ACEI/ARB, 
Covariate 
ACEI/ARB 
users (%) 
Control group 
(%) 
p value 
Baseline 56.19 60.76 0.37 
Year 1 92.19 93.05 0.799 
Year 2 88.52 92.29 0.308 
Year 3 45.53 57.25 0.015 
Year 4 50 56.68 0.148 
Year 5 53.02 62.57 0.029 
Year 6 48.8 62.16 0.0015 
Year 7 47.46 59.4 0.0039 
Year 8 50.48 60.23 0.0125 
Year 9 57.97 63.66 0.1377 
Year 10 49.59 53.59 0.285 
Year 11 57.02 61.18 0.2605 
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as suggested by data in Table 4.28. CHF as a time dependent covariate was therefore 
included in the multivariable model. 
 
Table 4.28: Percentage of subjects with CHF at baseline and each follow-up year in both the 
exposed and the control groups for specific aim 2 
 
 
Table 4.29: Cox regression model results for the effect of the use ACEI and/or ARB on the time to 
develop CHF for specific aim 2 
 
Similarly, the percentage of subjects who developed diabetes over the 11 years 
of follow-up in both the exposed and the control group are presented in table 4.30. It 
appears that there was for the most part no statistically significant difference between 
the 2 groups in terms of development of diabetes during the study. Cox model showed 
Development of CHF 
ACEI/ARB  
users (%) 
Control  
group (%) 
p value 
Baseline 0 0 - 
Year 1 0 1.08 0.614 
Year 2 1.9 0.9 0.278 
Year 3 1.96 2.42 1.00 
Year 4 8.06 2.2 0.0013 
Year 5 9.42 4.64 0.024 
Year 6 13.82 5.45 < 0.0001 
Year 7 15.03 6.71 0.0006 
Year 8 17.37 8.09 0.0002 
Year 9 21.27 9.25 < 0.0001 
Year 10 24.07 10.15 < 0.0001 
Year 11 22.63 11.04 < 0.0001 
Analysis of Maximum Likelihood Estimates 
Variable DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio (HR) 
95% HR  
Confidence Limits 
Use of ACEI and/or 
ARB 
1 0.23203 0.21372 1.1788 0.2776 1.261 0.83 1.92 
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that the time to develop diabetes was not different between those who used ACEI/ARB 
and the control group, as shown in table 4.31 below. These data suggested that any 
difference in incident cardiovascular events between the two groups during the follow-
up period would not probably be due to a difference in development of diabetes during 
the study. 
 
Table 4.30: Percentage of subjects diagnosed with diabetes at each follow-up year in both the 
exposed and the control groups for specific aim 2 
 
 
Table 4.31: Cox regression model results for the effect of the use of ACEI and/or ARB on the time 
to develop type 2 diabetes for specific aim 2 
 
 
 
Diabetes diagnosis 
ACEI/ARB  
users (%)s 
Control 
group (%) 
p value 
Baseline 0 0 - 
Year 1 0.95 0.09 0.165 
Year 2 0.98 0.18 0.231 
Year 3 0.81 0.37 0.417 
Year 4 0.71 1.02 1.00 
Year 5 3.95 2.54 0.290 
Year 6 2.31 0.86 0.1003 
Year 7 3.16 1.27 0.10 
Year 8 4.52 1.41 0.0059 
Year 9 5.81 3.79 0.207 
Year 10 4.38 2.23 0.0594 
Year 11 5.10 2.71 0.059 
Analysis of Maximum Likelihood Estimates 
Variable DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio (HR) 
95% HR Confidence 
 Limits 
Use of ACEI and/or  
ARB 
1 0.15416 0.39809 0.1500 0.6986 1.167 0.54 2.55 
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Results 
Specific Aim 1: Identify the effect of ACEI/ARB on the long 
term development of cardiovascular events in elderly non-
diabetic hypertensive patients with metabolic syndrome 
Study Number 1: The metabolic syndrome was defined based on the WHO 
Criteria 
A) Consideration of Age as an Independent Variable 
 
In order to test for the linearity of this variable, the -2 log likelihood value was 
compared between the model with age as categorical variable and the model with age as 
a linear variable. The difference in -2 log likelihood was equal to 21.9 which is larger 
than (א211, 0.05= 19.68) suggesting a trend for non-linearity. Therefore, age was added in 
the model as three levels according to the classical geriatric classification: 65 to 74 
years, 75 to 84 years, and 85 years and older. 
B) Univariate Analyses of the Independent Variables 
 
The results of the univariate analyses are shown in table 4.32 below. The 
variables that were found to have a statistically significant effect on the time to 
incidence of cardiovascular event included: age, gender, smoking status, race, number 
of alcohol beverages, exercise intensity level, BMI and HDL (p-value < 0.25). Among 
the time dependent variables, the use of ACEI/ARB, SBP, development of CHF and the 
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total number of antihypertensive medications were significantly associated with the 
outcome. 
Table 4.32: Univariate analyses using the WHO definition for the metabolic syndrome 
 
C) The Multivariable Model 
 
We included the variables that were statistically significant in the univariate 
analysis. We then tested the variables that lost their significant effect upon inclusion in 
the multivariable model as well as the variables that were not significant in the 
Variable DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio 
Age (75-84) vs. (65-74) 1 0.356 0.117 9.259 0.0023 1.4 
Age (≥ 85) vs. (65-74) 1 1.114 0.277 16.21 <0.0001 3.05 
Gender (male vs. female) 1 0.54629 0.10891 25.1585 <.0001 1.727 
Smoking(former vs. never) 1 0.27339 0.11758 5.4060 0.0201 1.314 
Smoking(current vs. never) 1 0.65925 0.16650 15.6768 <.0001 1.933 
Race (black vs. other) 1 -0.39833 0.19866 4.0202 0.0450 0.671 
# alcohol beverages 1 0.01053 0.00699 2.2686 0.1320 1.011 
Aspirin use  1 0.01881 0.11748 0.0256 0.8728 1.019 
Exercise intensity level 1 0.08456 0.07055 1.4366 0.2307 1.088 
BMI  1 -0.02344 0.01381 2.8817 0.0896 0.977 
Income level  1 0.00438 0.02783 0.0248 0.8749 1.004 
Family hx of MI 1 0.08371 0.11718 0.5103 0.4750 1.087 
Triglycerides 1 0.0006823 0.0008630 0.6251 0.4292 1.001 
HDL  1 -0.01012 0.00414 5.9671 0.0146 0.990 
LDL  1 0.0005222 0.00160 0.1059 0.7449 1.001 
Time dependent covariates 
ACEI/ARB use 1 -0.23604 0.16588 2.0248 0.1548 0.790 
SBP 1 0.00857 0.00250 11.7398 0.0006 1.009 
Development of diabetes 1 0.20660 0.36106 0.3274 0.5672 1.229 
Development of CHF 1 1.84290 0.14976 151.4211 <.0001 6.315 
Number of HTN 
 medications 
1 -0.12568 0.05359 5.4989 0.0190 0.882 
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univariate analysis for any confounding effect. Tests for interactions between the 
exposure variable and age, race, gender were also conducted (for details, see model 
building technique section in chapter 3). However, none of these interactions were 
found to be statistically significant. The final model is presented in table 4.33 below. 
Table 4.33: Multivariable model using the WHO definition for the metabolic syndrome 
 
 
The hazard ratio for the incidence of any cardiovascular event in the exposed 
group was found to be equal to 0.72 compared to the control group suggesting that the 
hazard for cardiovascular events for those exposed to the drug of interest was only 
about 72% of the hazard for those who were not exposed to ACEI or ARB. The 95% 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-
value 
Hazard 
Ratio 
(HR) 
95% HR Confidence 
Limits 
Use of ACEI/ARB 1 -0.33210 0.17586 3.5664 0.0590 0.717 0.508 1.013 
SBP 1 0.00667 0.00251 7.0548 0.0079 1.007 1.002 1.012 
Development of CHF 1 1.80697 0.15552 134.9960 <.0001 6.092 4.491 8.263 
Development of 
diabetes 
1 0.52760 0.36572 2.0812 0.1491 1.695 0.828 3.471 
# HTN medications 1 -0.09475 0.05534 2.9317 0.0869 0.910 0.816 1.014 
Age (75-84) 
vs. (65-74) 
1 0.27609 0.12010 5.2847 0.0215 1.318 1.042 1.668 
Age (≥ 85) 
vs. (65-74)  
1 0.90380 0.28359 10.1570 0.0014 2.469 1.416 4.304 
Gender (male vs. 
female) 
1 0.56275 0.11602 23.5264 <.0001 1.755 1.398 2.204 
Former smoker vs. 
never 
1 0.18128 0.12278 2.1801 0.1398 1.199 0.942 1.525 
Current smoker vs. 
never 
1 0.68065 0.17053 15.9315 <.0001 1.975 1.414 2.759 
Race (black vs. not) 1 -0.39441 0.20183 3.8189 0.0507 0.674 0.454 1.001 
LDL  1 0.00321 0.00168 3.6718 0.0553 1.003 1.000 1.007 
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C.I. (0.51, 1.01) suggested that the exposure to either ACEI/ARB had a non-statistically 
significant effect on the time to develop CVD. 
D) Testing the Proportional Hazard Assumption 
 
1) We included interactions between each independent variable and log (time) to 
test for the proportional hazard assumption. Table 4.34 below presents the estimated 
coefficients, standard errors, Wald statistics and p-values for the Wald statistics of the 
interactions with log-time. 
Table 4.34: Testing the proportional hazard assumption by including interactions of independent 
variables with time using the WHO definition for the metabolic syndrome 
 
 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-
value 
Hazard 
Ratio 
(HR) 
95% HR Confidence 
Limits 
Age level (65-
74)*log(time) 
1 0.18529 0.24622 0.5663 0.4517 1.204 0.743 1.950 
Age level (75-
84)*log(time) 
1 0.02832 0.24517 0.0133 0.9080 1.029 0.636 1.663 
Use of 
ACEI/ARB*log(time) 
1 -0.09601 0.21330 0.2026 0.6526 0.908 0.598 1.380 
SBP*log(time) 1 -0.00284 0.00273 1.0809 0.2985 0.997 0.992 1.003 
Development of 
CHF*log(time) 
1 -0.23373 0.16673 1.9650 0.1610 0.792 0.571 1.098 
Development of diabetes 
*log(time) 
1 0.40027 1.23926 0.1043 0.7467 1.492 0.132 16.932 
Gender*log(time) 1 -0.20369 0.13168 2.3927 0.1219 0.816 0.630 1.056 
Never smoking*log(time) 1 -0.14138 0.19661 0.5171 0.4721 0.868 0.591 1.276 
Former smoking*log(time) 1 -0.21399 0.18802 1.2953 0.2551 0.807 0.558 1.167 
Race*log(time) 1 -0.08465 0.22570 0.1407 0.7076 0.919 0.590 1.430 
LDL*log(time) 1 -0.00062 0.00179 0.1216 0.7273 0.999 0.996 1.003 
Number of  HTN 
medications*log(time) 
1 0.19008 0.06576 8.3542 0.0038 1.209 1.063 1.376 
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As can be seen from the table above, the “number of antihypertensive 
medications” variable seemed to have a significant interaction with time, suggesting 
that this variable might violate the proportional hazard assumption. Therefore, the 
interaction of this variable with log (time) needed to be added to the model.  
2) The proportional hazard assumption was also tested by examining a plot of 
the scaled Schoenfeld residuals from the model without the interactions terms with 
time. Each subplot had a slope essentially equal to zero suggesting that the proportional 
hazard assumption was met for all the variables except for the “number of 
antihypertensive medications” variable (see appendix B for details). 
3) Testing the proportional hazard assumption using the rank test as shown in 
table 4.35. 
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Table 4.35: Testing the proportional hazard assumption by the rank test using the WHO definition 
for the metabolic syndrome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The p-value for the global test of the rank test was statistically significant 
suggesting that the proportional hazard assumption might be violated. However, after 
including the interaction between the “number of antihypertensive medications” and 
time to the model, the overall global test was no longer statistically significant as shown 
in table 4.36. 
 
 
Variable Rho Chi DF p-value 
Use of ACEI/ARB -0.036 0.47 1 0.495 
Development of CHF -0.026 0.25 1 0.619 
Development of diabetes 0.0198 0.13 1 0.715 
SBP -0.06762 1.47 1 0.2261 
Number of HTN  
medications 
0.14515 8.21 1 0.0042 
Age (75-84) vs. (65-74)l -0.064 1.45 1 0.2292 
Age (≥ 85) vs. (65-74) -0.0976 3.33 1 0.0679 
Gender -0.09958 3.46 1 0.063 
Past smokers vs.  
never smokers 
-0.0525 0.96 1 0.3274 
Current smokers  
vs. never smokers 
0.04508 0.7 1 0.4043 
Race -0.05702 1.08 1 0.2995 
LDL -0.01173 0.06 1 0.8138 
     
Global test  23.88 12 0.021 
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Table 4.36: Testing the proportional hazard assumption by the rank test for the modified model 
using the WHO definition for the metabolic syndrome 
 
 
 
 
 
 
 
 
 
 
 
 
E) The Modified Multivariable Model 
The interaction between the “number of anti-hypertensives used” and log “time” 
was added to the multivariable model. The result is presented in table 4.37 below. 
Variable Rho Chi DF p-value 
Use of ACEI/ARB -0.0328 0.4 1 0.5262 
Development of CHF -0.0247 0.23 1 0.634 
Development of diabetes 0.0162 0.09 1 0.7662 
SBP -0.065 1.39 1 0.239 
Number of HTN  
medications 
-0.0004 0.00 1 0.9932 
Age (75-84) vs. (65-74) -0.063 1.41 1 0.2353 
Age (≥ 85) vs. (65-74) 
 
-0.0927 2.99 1 0.0835 
Gender -0.097 3.28 1 0.0708 
Past smokers  
vs. never smokers 
-0.0517 0.93 1 0.334 
Current smokers  
vs. never smokers 
0.043 0.65 1 0.419 
Race -0.0504 0.83 1 0.3616 
LDL -0.013 0.07 1 0.788 
Number of HTN  
medications *log(time) 
0.0063 0.02 1 0.899 
     
Global test  15.04 13 0.305 
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Table 4.37: Modified multivariable model using the WHO definition for the metabolic syndrome 
 
 
As can be seen from table 4.37, exposure to either ACEI/ARB had a significant 
effect on the time to develop CVD. The hazard for cardiovascular events for those 
exposed to the drug of interest was only about 68% of the hazard for those who were 
not exposed to ACEI or ARB when using the WHO definition. 
F) Survival Plot 
 
Cox regression survival plot for the multivariable model is presented in figure 
4.6 below. Survival estimates for the exposed group (exposed to ACEI/ARB) were 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-
value 
Hazard 
Ratio 
(HR) 
95% HR Confidence 
Limits 
Use of ACEI/ARB 1 -0.38385 0.17840 4.6296 0.0314 0.681 0.480 0.966 
SBP 1 0.00627 0.00253 6.1579 0.0131 1.006 1.001 1.011 
Development of CHF 1 1.82024 0.15620 135.7942 <.0001 6.173 4.545 8.385 
Development of 
diabetes 
1 0.50311 0.36598 1.8897 0.1692 1.654 0.807 3.389 
 Number of HTN 
medications 
1 -1.41579 0.45350 9.7465 0.0018 0.243 0.100 0.590 
Age (75-84) vs. (65-
74)  
1 0.28217 0.12001 5.5280 0.0187 1.326 1.048 1.678 
Age (≥ 85) vs. (65-74) 1 0.94021 0.28360 10.9913 0.0009 2.561 1.469 4.464 
Gender (male vs. 
female) 
1 0.56108 0.11614 23.3405 <.0001 1.753 1.396 2.201 
Former smoker  
vs. never 
1 0.18516 0.12292 2.2691 0.1320 1.203 0.946 1.531 
Current smoker  
vs. never 
1 0.67930 0.17057 15.8603 <.0001 1.972 1.412 2.756 
Race (black vs. not) 1 -0.35993 0.20223 3.1678 0.0751 0.698 0.469 1.037 
LDL 1 0.00328 0.00168 3.8061 0.0511 1.003 1.000 1.007 
Number of HTN 
medications*log (time) 
1 0.18356 0.06201 8.7617 0.0031 1.201 1.064 1.357 
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significantly higher than the control group; suggesting that the exposure to ACEI/ARB 
in hypertensive non-diabetic subjects with the metabolic syndrome according to the 
WHO criteria, had a significant protective effect against the development of CVD. 
 
Figure 4.6: Cox regression survival plot using the WHO definition for the 
metabolic syndrome 
 
 
 
 
 
 
 
 
 
 
G) Influence Diagnostics 
G.1 Deviance residuals: 
Deviance residuals behave like residuals from the ordinary least squares 
regression: they are symmetrically distributed around zero and have an approximated 
standard deviation of one. They are negative for observations that have longer survival 
times than expected and positive for observations with survival times shorter than 
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expected (122). Therefore, very high or low values suggest that the observation may be 
an outlier and needs special attention. 
Deviance residual plot is shown in figure 4.7 below. We noticed the 2 clusters 
that were due to censoring; the upper portion represented the uncensored subjects and 
the lower portion represented the censored subjects. None of the observations seemed to 
be of a striking distance between the other points indicating that there did not appear to 
be any outliers. 
Figure 4.7: Deviance residuals plot using the WHO definition for the metabolic 
syndrome 
 
 
G.2 DFBETA statistic 
DFBETA statistics tell us how much each coefficient changes by removal of a 
single observation from the sample (122). DFBETA was calculated for each variable 
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and none of the variables had exceptionally large values (DFBETA ≥ 2) for any of the 
DFBETAs. DFBETA for the use of ACEI/ARB ranged from -0.0179 to 0.0299; -0.0147 
to 0.023 for CHF; -0.05 to 0.13 for diabetes; -0.00034 to 0.0004 for SBP; -0.063 to 0.17 
for the number of antihypertensive medications; -0.036 to 0.028 for age; -0.012 to 0.012 
for gender; -0.011 to 0.0099 for former smoking; -0.0147 to 0.0245 for current 
smoking; -0.013 to 0.037 for race; -0.0002 to 0.00028 for LDL; -0.022 to 0.01 for the 
interaction between the number of antihypertensive medications and time. Thus, we 
may conclude that there were no unusually influential observations. 
Study Number 2: The metabolic syndrome was defined based on the EGIR 
criteria 
A) Consideration of Age as an Independent Variable 
 
The difference in -2 log likelihood between the model that included age as a 
categorical variable and the model where age was treated as continuous was equal to 
19.568 which is smaller than א211, 0.05= 19.68 suggesting that there was no trend for non-
linearity. Thus age was treated as a continuous variable. Sensitivity analysis using age 
as a categorical variable was also performed (see Appendix A for details). 
B) Univariate Analysis of the Independent Variables 
 
Table 4.38 below presents the results of the univariate analyses for all the 
independent variables. The variables that were found to have a statistically significant 
effect on the time to incidence of cardiovascular event included: age, gender, current 
smokers vs. never, race, HDL level, and the triglycerides level. Among the time 
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dependent variables, SBP, the “total number of antihypertensive medications” and the 
development of CHF were significantly associated with the outcome.
  88
 
Table 4.38: Univariate analyses using the EGIR definition for the metabolic syndrome 
 
C) The Multivariable Model 
 
We included the variables that were statistically significant in the univariate 
analysis. We then tested the variables that lost their significant effect upon inclusion in 
the multivariable model as well as the variables that were not significant in the 
univariate analysis for any confounding effect. Tests for interactions between the 
exposure variable and age, race, gender were also conducted (see model building 
Variable DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio 
Age 1 0.05643 0.01271 19.7063 <.0001 1.058 
Gender (male vs. female) 1 0.38279 0.12720 9.0564 0.0026 1.466 
Smoking(former vs. never) 1 0.12462 0.13881 0.8060 0.3693 1.133 
Smoking(current vs. never) 1 0.73898 0.18651 15.6979 <.0001 2.094 
Race (black vs. other) 1 -0.31306 0.21641 2.0927 0.1480 0.731 
# alcohol beverages 1 0.00431 0.00884 0.2380 0.6257 1.004 
Aspirin use  1 0.13614 0.13590 1.0034 0.3165 1.146 
Exercise intensity level 1 0.05048 0.08130 0.3856 0.5346 1.052 
BMI  1 -0.01340 0.01671 0.6430 0.4226 0.987 
Income level  1 -0.00497 0.03342 0.0221 0.8819 0.995 
Family hx of MI 1 0.12877 0.13785 0.8726 0.3502 1.137 
Triglycerides 1 0.00178 0.00102 3.0013 0.0832 1.002 
HDL  1 -0.01207 0.00479 6.3663 0.0116 0.988 
LDL  1 0.0005307 0.00190 0.0783 0.7796 1.001 
Time dependent covariates 
ACEI/ARB use 1 0.06298 0.18340 0.1179 0.7313 1.065 
SBP 1 0.00857 0.00313 7.4916 0.0062 1.009 
Development of diabetes 1 0.33991 0.45428 0.5599 0.4543 1.405 
Development of CHF 1 1.64961 0.18367 80.6611 <.0001 5.205 
Number of HTN  
medications 
1 -0.07516 0.06013 1.5623 0.2113 0.928 
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technique section in chapter 3 for details). However, none of these interactions were 
found to be statistically significant. The final model is presented in table 4.39 below. 
Table 4.39: Multivariable model using the EGIR definition for the metabolic syndrome 
 
 
As can be seen, exposure to either ACEI/ARB had no significant effect on the 
incidence of cardiovascular events. The hazard ratio for the incidence of any 
cardiovascular event in the exposed group was found to be equal to 0.93 compared to 
the control group with a 95% C.I. (0.63, 1.377) suggesting that the hazard for 
cardiovascular events for those exposed to the drug of interest was not statistically 
different from the hazard for those who were not exposed to ACEI or ARB. 
D) Testing the Proportional Hazard Assumption 
 
1) We included interactions between each variable and log (time) to test for the 
proportional hazard assumption as presented in table 4.40 below. The table shows the 
interactions as well as the estimated coefficients, standard errors, Wald statistics and p-
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
(HR) 
95% HR 
Confidence  
Limits 
Use of ACEI/ARB 1 -0.07112 0.19951 0.1271 0.7215 0.931 0.630 1.377 
SBP 1 0.00698 0.00311 5.0262 0.0250 1.007 1.001 1.013 
Development of CHF 1 1.58336 0.18915 70.0710 <.0001 4.871 3.362 7.057 
Development of diabetes 1 0.67224 0.46090 2.1273 0.1447 1.959 0.794 4.834 
Number of HTN 
medications  
1 -0.10036 0.06482 2.3971 0.1216 0.905 0.797 1.027 
Age 1 0.04805 0.01254 14.6774 0.0001 1.049 1.024 1.075 
Gender (males vs. females) 1 0.30685 0.13385 5.2558 0.0219 1.359 1.046 1.767 
Former smoker vs. never 1 0.07297 0.14562 0.2511 0.6163 1.076 0.809 1.431 
Current smoker vs. never 1 0.75934 0.19119 15.7735 <.0001 2.137 1.469 3.108 
Race (black vs. other)  1 -0.36477 0.22018 2.7446 0.0976 0.694 0.451 1.069 
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values (the main effects alone are not shown). Wald test for each interaction with time 
was not statistically significant suggesting that the proportional hazard was most likely 
met for all the variables except for the “total number of anti-hypertensives” variable. 
Table 4.40: Testing the proportional hazard assumption by including interactions of independent 
variables with time using the EGIR definition for the metabolic syndrome 
 
 
2) The proportional hazard assumption was also tested by examining a plot of 
the scaled Schoenfeld residuals from the model without the interactions terms with 
time. Each subplot had a slope essentially equal to zero except for the “total number of 
antihypertensives” suggesting that the proportional hazard assumption was met for all 
the variables except this variable (see appendix B for details). 
3) Testing the proportional hazard assumption using the rank test as shown in 
table 4.41 below. 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-
value 
Hazard 
Ratio 
(HR) 
95% HR Confidence 
Limits 
Use of ACEI/ARB *log(time) 1 -0.01096 0.24665 0.0020 0.9646 0.989 0.610 1.604 
SBP*log(time) 1 -0.00421 0.00351 1.4395 0.2302 0.996 0.989 1.003 
Development of 
CHF*log(time) 
1 0.48713 0.38753 1.5801 0.2087 1.628 0.762 3.479 
Development of 
diabetes*log(time) 
1 0.07233 1.21649 0.0035 0.9526 1.075 0.099 11.665 
Number of HTN medications 
*log(time) 
1 0.16075 0.07946 4.0928 0.0431 1.174 1.005 1.372 
Age *log(time) 1 -0.03043 0.01329 5.2461 0.0220 0.970 0.945 0.996 
Gender*log(time) 1 -0.16581 0.15451 1.1516 0.2832 0.847 0.626 1.147 
Former smoking*log(time) 1 0.00787 0.22297 0.0012 0.9719 1.008 0.651 1.560 
Past smoking*log(time) 1 -0.21904 0.21596 1.0287 0.3105 0.803 0.526 1.227 
Race*log(time) 1 -0.18014 0.25158 0.5127 0.4740 0.835 0.510 1.367 
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Table 4.41: Testing the proportional hazard assumption by the rank test using the EGIR definition 
for the metabolic syndrome 
 
 
From the previous analysis to test the proportional hazard assumption, we 
noticed that one variable might violate this assumption “the total number of 
antihypertensive medications”. Therefore, the final modified multivariable model 
included the previously mentioned variables and the interaction between the total 
number of anti-hypertensives with time. 
Variable Rho Chi DF p-value 
Use of ACEI/ARB -0.031 0.25 1 0.619 
Development of CHF    0.122 3.58 1 0.059 
Development of diabetes   0.0097 0.02 1 0.8778 
SBP   -0.0886 1.73 1 0.189 
Age  -0.116 3.22 1 0.073 
Number of HTN medications 0.125 4.0 1 0.046 
Gender   -0.079 1.6 1 0.206 
Former smoker vs. never smoker  -0.092 2.27 1 0.132 
Current smoker vs. never smoker 0.014 0.05 1 0.829 
Race   -0.089 1.95 1 0.163 
     
Global test  18.6 10 0.0455 
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E) The Modified Multivariable Model  
 
The final modified multivariable model included the interaction between the 
total number of anti-hypertensives with time as shown in table 4.42. 
 
Table 4.42: Modified multivariable model using the EGIR definition for the metabolic syndrome 
 
 
Exposure to either ACEI/ARB had no statistically significant effect on the 
incidence of cardiovascular events using the EGIR definition of metabolic syndrome. 
The hazard ratio for the incidence of any cardiovascular event in the exposed group was 
found to be equal to 0.89 compared to the control group with a 95% C.I. (0.6, 1.33) 
suggesting that the hazard for cardiovascular events for those exposed to the drug of 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-
value 
Hazard 
Ratio 
(HR) 
95% HR Confidence 
Limits 
Use of ACEI/ARB 1 -0.10970 0.20204 0.2948 0.5872 0.896 0.603 1.331 
SBPI 1 0.00677 0.00311 4.7522 0.0293 1.007 1.001 1.013 
Development of CHF 1 1.58319 0.18986 69.5356 <.0001 4.870 3.357 7.066 
Development of 
diabetes 
1 0.64936 0.46179 1.9773 0.1597 1.914 0.774 4.733 
Number of HTN  
medications 
1 -1.19545 0.54971 4.7292 0.0297 0.303 0.103 0.889 
Age 1 0.04939 0.01259 15.3776 <.0001 1.051 1.025 1.077 
Gender (male vs. 
female) 
1 0.30223 0.13399 5.0880 0.0241 1.353 1.040 1.759 
Former smoker vs. 
never 
1 0.08302 0.14582 0.3242 0.5691 1.087 0.816 1.446 
Current smoker vs. 
never 
1 0.76748 0.19120 16.1129 <.0001 2.154 1.481 3.134 
Race (black vs. other) 1 -0.33256 0.22084 2.2678 0.1321 0.717 0.465 1.105 
Number of HTN 
medications *log 
(time) 
1 0.15060 0.07451 4.0853 0.0433 1.163 1.005 1.345 
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interest was not statistically different from the hazard for those who were not exposed to 
ACEI or ARB for the EGIR definition. 
F) Survival Plot 
Cox regression survival plot for the multivariable model is presented in figure 
4.8 below. Survival estimates for the exposed group (exposed to ACEI/ARB) were not 
significantly higher than the control group; suggesting that the exposure to ACEI/ARB 
in hypertensive non-diabetic subjects with the metabolic syndrome according to the 
EGIR criteria, had no significant protective effect against the development of CVD. 
Figure 4.8: Cox regression survival plot using the EGIR definition for the 
metabolic syndrome 
 
 
G) Influence Diagnostics 
G.1 Deviance residuals 
Figure 4.9 shows that none of the observations seem to be of a striking distance 
from the other points indicating that there did not appear to be any outliers. 
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Figure 4.9: Deviance residuals plot using the EGIR definition for the metabolic 
syndrome 
 
 
G.2 DFBETA statistic 
DFBETA was calculated for each variable and none of the variables had 
exceptionally large values for any of the DFBETAs; none of the DFBETAs was ≥ 2. 
DFBETA for the use of ACEI/ARB ranged from -0.0197 to 0.039; -0.0166 to 0.035 for 
CHF; -0.023 to 0.199 for diabetes;-0.00055 to 0.00055 for SBP;-0.08 to 0.193 for the 
number of anti-hypertensives used; -0.042 to 0.038 for age; -0.013 to 0.015 for gender; -
0.016 to 0.016 for former smoking; -0.017 to 0.031 for current smoking; -0.013 to 0.046 
for race; -0.025 to 0.0125 for the interaction between the number of anti-hypertensives 
and time. Thus, we may conclude that there were no unusually influential observations. 
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Study Number 3: The metabolic syndrome was defined based on the ATP 
Criteria 
A) Consideration of Age as an Independent Variable 
 
The -2 log likelihood for the model where age was treated as a continuous 
variable was equal to 3236.283, -2 log likelihood for the model with age as a 13 level 
categorical variable was equal to 3221.402. The difference between the -2 log 
likelihood for the 2 models was equal to 14.88 which is less than א 211, 0.05= 19.68 
suggesting no trend for non-linearity. Thus, age was included in the model as a 
continuous variable. Sensitivity analysis using age as a categorical variable was also 
performed (see Appendix A for details). 
B) Univariate Analysis of the Independent Variables 
 
The results of the univariate analyses are shown in table 4.43 below. Most of the 
independent variables had a statistically significant effect on the time to develop CVD 
except for the following: BMI, income level, family history of MI and LDL level. 
Among the time dependent variables, only one variable “development of diabetes” had 
no statistically significant effect on the outcome of interest. 
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Table 4.43: Univariate analyses using the ATP definition for the metabolic syndrome 
 
C) The Multivariable Model 
 
In the multivariable model, the level of HDL at baseline, aspirin use, exercise 
intensity level, the number of alcohol beverages and the total number of anti-
hypertensives lost their significant p value and were removed from the multivariable 
model. However, LDL level at baseline was found to be significantly associated with 
the time to develop any cardiovascular event after adjusting for other variables (for 
details on our approach to determine the final model, see model building technique 
Variable DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio 
Age 1 0.05025 0.01227 16.7605 <.0001 1.052 
Gender (male vs. female) 1 0.71269 0.12598 32.0021 <.0001 2.039 
Smoking(former vs. never) 1 0.30989 0.13745 5.0830 0.0242 1.363 
Smoking(current vs. never) 1 0.76511 0.18055 17.9580 <.0001 2.149 
Race (black vs. other) 1 -0.47588 0.25239 3.5550 0.0594 0.621 
# alcohol beverages 1 0.01646 0.00825 3.9804 0.0460 1.017 
Aspirin use 1 0.16044 0.13212 1.4746 0.2246 1.174 
Exercise intensity level 1 0.11705 0.08143 2.0662 0.1506 1.124 
BMI 1 -0.01151 0.01637 0.4949 0.4817 0.989 
Income level 1 0.02912 0.03296 0.7808 0.3769 1.030 
Family hx of MI 1 0.01301 0.13451 0.0094 0.9230 1.013 
Triglycerides 1 0.00194 0.0009438 4.2173 0.0400 1.002 
HDL 1 -0.01376 0.00549 6.2759 0.0122 0.986 
LDL 1 0.00137 0.00181 0.5755 0.4481 1.001 
Time dependent covariates 
Use of ACEI/ARB 1 -0.24629 0.20481 1.4461 0.2292 0.782 
SBP 1 0.00814 0.00299 7.4268 0.0064 1.008 
Development of diabetes 1 0.02940 0.41767 0.0050 0.9439 1.030 
Development of CHF 1 1.96322 0.17102 131.7789 <.0001 7.122 
Number of HTN 
medications 
1 -0.08069 0.05998 1.8100 0.1785 0.922 
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section in chapter 3). The final model included our variable of interest (exposure to 
ACEI/ ARB), the variables with a significant effect, as well as any variables that were 
found to confound the results. We tested for different interactions between the use of 
ACEI/ARB and race, age as well as gender. However, none of these interactions had 
any significant effects. The multivariable model is presented in table 4.44 below. 
Table 4.44: Multivariable model using the ATP definition for the metabolic syndrome 
 
 
After adjusting for the different confounding variables, the use of ACEI or ARB 
was found to reduce the hazard to develop any incident cardiovascular event when 
using the ATP definition. The hazard ratio associated with the use of either ACEI or 
ARB was found to be equal to 0.66 with a 95 % confidence interval (0.43, 0.99). This 
result suggests that the hazard to develop CVD with the use of ACEI/ARB is only 66% 
of the hazard for those who were not exposed to ACEI/ARB. 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio (HR) 
95% HR 
Confidence Limits 
Use of ACEI/ARB 1 -0.41856 0.20996 3.9743 0.0462 0.658 0.436 0.993 
Development of CHF  1 2.02361 0.18044 125.7765 <.0001 7.566 5.312 10.775 
SBP 1 0.00729 0.00300 5.9084 0.0151 1.007 1.001 1.013 
Development of diabetes 1 0.34978 0.42389 0.6809 0.4093 1.419 0.618 3.256 
Age  1 0.03441 0.01264 7.4108 0.0065 1.035 1.010 1.061 
Gender (male vs. female) 1 0.76092 0.13494 31.7965 <.0001 2.140 1.643 2.788 
Former smoker vs. never 1 0.19716 0.14391 1.8768 0.1707 1.218 0.919 1.615 
Current smoker vs. never 1 0.76167 0.18661 16.6595 <.0001 2.142 1.486 3.088 
Race (black vs. other) 1 -0.21260 0.25750 0.6817 0.4090 0.808 0.488 1.339 
Triglycerides 1 0.00272 0.0009689 7.8946 0.0050 1.003 1.001 1.005 
LDL  1 0.00445 0.00183 5.8774 0.0153 1.004 1.001 1.008 
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D) Survival Plot 
 
Cox regression survival plot for the multivariable model is presented in figure 
4.10 below. Survival estimates for the exposed group (exposed to ACEI/ARB) were 
significantly higher than the control group, suggesting that the exposure to ACEI/ARB 
in hypertensive non-diabetic subjects with the metabolic syndrome defined by the ATP 
criteria, has significant protective effect against the development of CVD. 
 
Figure 4.10: Cox regression survival plot using the ATP definition for the 
metabolic syndrome 
 
 
E) Testing the Proportional Hazard Assumption 
 
1) We added interactions of each main effect with log (time) to the model to 
evaluate the proportional hazard assumption. Table 4.45 below presents the estimated 
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coefficients, standard errors, Wald statistics and p-values for the Wald statistics for the 
interactions with log-time. Wald test for each interaction with time was not statistically 
significant suggesting that the proportional hazard is most likely met. 
 
Table 4.45: Testing the proportional hazard assumption by including interactions of independent 
variables with time using the ATP definition for the metabolic syndrome 
 
2) The proportional hazard assumption was also tested by examining a plot of 
the scaled Schoenfeld residuals from the model without the interactions terms with. 
time. Each subplot has a slope essentially equal to zero suggesting that the proportional 
hazard assumption is met for all the variables (see appendix B for details). 
Variable  DF 
Parameter 
Estimates 
Standard  
Error  
Chi-Square p-value 
Hazard  
Ratio  
(HR) 
95% Confidence 
Interval 
Use of ACEI/ARB  
* log(t) 
1 -0.37253 0.20160 3.415 0.065 0.689 0.464 1.023 
Age *log(t) 1 -0.00997 0.01281 0.605 0.437 0.990 0.966 1.015 
Gender * log(t) 1 -0.15045 0.14846 1.027 0.311 0.860 0.643 1.151 
Never Smoking  
vs. current *log(t) 
1 -0.03530 0.20768 0.029 0.865 0.965 0.643 1.450 
Former smoking  
vs. current*log(t) 
1 -0.08442 0.19994 0.178 0.673 0.919 0.621 1.360 
Race *log(t) 1 0.07825 0.29487 0.070 0.791 1.081 0.607 1.927 
LDL *log(t) 1 0.0003081 0.00198 0.024 0.876 1.000 0.996 1.004 
Triglycerides * 
log(t) 
1 -0.00154 0.00096
17 
2.564 0.109 0.998 0.997 1.000 
Development of 
CHF *log(t) 
1 -0.19671 0.20197 0.949 0.331 0.821 0.553 1.220 
Development of 
diabetes *log(t) 
1 1.19552 1.80094 0.441 0.507 3.305 0.097 
112.7
64 
SBP *log(t) 1 -0.00221 0.00329 0.452 0.502 0.998 0.991 1.004 
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3) The proportional hazard assumption was tested using the rank test as shown 
in table 4.46 below. All of the variables seem to satisfy the proportional hazard 
assumption except for “the use of ACEI/ARB” variable (p value = 0.045). 
Table 4.46: Testing the proportional hazard assumption by the rank test using the ATP definition 
for the metabolic syndrome 
 
 
 
 
 
 
 
 
 
 
 
As can be seen from table 4.46 above, the variable “use of ACEI and/or ARB” 
might not satisfy the proportional hazard assumption. Therefore, another possible model 
that might be fitted is the model where this variable is treated as time-varying covariate; 
which means that besides allowing the value of that variable to change over time, the 
effect of that variable is allowed to interact with the follow-up time. The final 
multivariable model in this case is presented in table 4.47 below. 
 
Variable rho Chi DF p-value 
Use of ACEI/ARB  -0.12 4.01 1 0.045 
CHF    -0.032 0.29 1 0.588 
Diabetes  0.024 0.15 1 0.6978 
SBP  -0.046 0.54 1 0.462 
Age  -0.042 0.48 1 0.489 
Gender  -0.096 2.28 1 0.1314 
Former smoking vs. never  -0.031 0.25 1 0.62 
Current smoking vs. never 0.018 0.08 1 0.7799 
Race    -0.0182 0.09 1 0.771 
Triglycerides -0.114 3.34 1 0.0675 
LDL  0.024 0.16 1 0.6892 
     
Global test  12.76 11 0.3095 
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Table 4.47: Alternative multivariable model using the ATP definition for the metabolic syndrome 
 
 
In this final model, we found that the interaction between the use of ACEI/ARB 
and time was not significant. Therefore, the final multivariable model that was adopted 
was the model presented in table 4.44 above.  
F) Influence Diagnostics 
F.1 Deviance residuals: 
Deviance residual plot is shown in figure 4.11 below. We notice the 2 clusters 
that are due to censoring; the upper portion represents the uncensored subjects and the 
lower portion represents the censored subjects. None of the observations seem to be of a 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio 
95% HR  
Confidence 
 Limits 
Use of ACEI/ARB 1 2.21262 1.43032 2.3930 0.1219 9.140 0.554 150.805 
Development of CHF 1 2.05242 0.18083 128.8252 <.0001 7.787 5.463 11.099 
SBP 1 0.00732 0.00300 5.9545 0.0147 1.007 1.001 1.013 
Development of diabetes 1 0.38538 0.42423 0.8252 0.3637 1.470 0.640 3.377 
Age category 1 0.03409 0.01263 7.2834 0.0070 1.035 1.009 1.061 
Gender 1 0.75911 0.13499 31.6241 <.0001 2.136 1.640 2.783 
Never smoker 1 0.19044 0.14409 1.7469 0.1863 1.210 0.912 1.605 
Former smoker 1 0.75705 0.18666 16.4495 <.0001 2.132 1.479 3.074 
Race (black vs. other) 1 -0.21965 0.25780 0.7260 0.3942 0.803 0.484 1.331 
Triglycerides 1 0.00272 0.0009718 7.8072 0.0052 1.003 1.001 1.005 
LDL 1 0.00452 0.00183 6.0913 0.0136 1.005 1.001 1.008 
Use of ACEI/ARB*log(t) 1 -0.35952 0.19679 3.3377 0.0677 0.698 0.475 1.027 
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striking distance between the other points indicating that there do not appear to be any 
outliers. 
Figure 4.11: Deviance residuals plot using the ATP definition for the metabolic 
syndrome 
 
 
F.2 DFBETA statistic 
DFBETA was calculated for each variable and none of the variables had 
exceptionally large values for any of the DFBETAs; DFBETAs were less than 2. 
DFBETA for the use of ACEI/ARB ranged from -0.0199 to 0.0415; -0.023 to 0.0279 
for CHF; -0.063 to 0.177 for diabetes, -0.0004 to 0.0006 for SBP; -0.147 to 0.147 for 
age; 0.0137 to 0.015 for gender; -0.015 to 0.017 for former smoking, -0.022 to 0.027 for 
current smoking; -0.0128 to 0.071 for race; -0.0003 to 0.0004 for LDL; -0.000097 to 
0.00018 for triglycerides. Thus, we may conclude that there were no unusually  
influential observations.
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Study Number 4: The metabolic syndrome was defined based on the AACE 
criteria 
 
A) Consideration of Age as an Independent Variable 
 
The difference in -2 log likelihood between the model with age as a categorical 
variable and the model where age was treated as a continuous variable was equal to 
18.025 which is less than א 211, 0.05= 19.68, suggesting no trend for non-linearity of the 
age variable. Thus age was included in the analysis as a continuous variable. Sensitivity 
analysis using age as a categorical variable was also performed (see Appendix A for 
details). 
B) Univariate Analysis of the Independent Variables 
 
The results of the univariate analyses of all the independent variables are shown 
in table 4.48 below. The variables that were found to have a significant effect on the 
time to incidence of CVD include: age, gender, smoking, race, HDL, BMI and income 
level. Among the time dependent variables, SBP, development of CHF were 
significantly associated with the outcome. 
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Table 4.48: Univariate analyses using the AACE definition for the metabolic syndrome 
 
C) The Multivariable Model 
 
We included the variables that were statistically significant in the univariate 
analysis. We then tested the variables that lost their significant effect upon inclusion in 
the multivariable model as well as the variables that were not significant in the 
univariate analysis for any confounding effect. Tests for interactions between the 
exposure variable and age, race, gender were also conducted (see model building 
technique section in chapter 3 for details). However, none of these interactions were 
Variable DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio 
Age 1 0.06014 0.00987 37.1412 <.0001 1.062 
Gender (male vs. female) 1 0.57561 0.10200 31.8425 <.0001 1.778 
Smoking(former vs. never) 1 0.25874 0.11080 5.4536 0.0195 1.295 
Smoking(current vs. never) 1 0.71888 0.15131 22.5721 <.0001 2.052 
Race (black vs. other) 1 -0.29623 0.19724 2.2558 0.1331 0.744 
# alcohol beverages 1 0.00385 0.00719 0.2860 0.5928 1.004 
Aspirin use  1 0.02942 0.11131 0.0698 0.7916 1.030 
Exercise intensity level 1 -0.01387 0.06751 0.0422 0.8372 0.986 
BMI  1 -0.02341 0.01377 2.8928 0.0890 0.977 
Income level  1 -0.03353 0.02618 1.6401 0.2003 0.967 
Family hx of MI 1 -0.03167 0.11159 0.0806 0.7765 0.969 
Triglycerides  1 0.0006736 0.0008584 0.6157 0.4327 1.001 
HDL  1 -0.00800 0.00386 4.2934 0.0383 0.992 
LDL  1 0.0008524 0.00151 0.3172 0.5733 1.001 
Time dependent covariates 
Use of ACEI/ARB 1 -0.06731 0.15676 0.1844 0.6677 0.935 
SBP 1 0.00812 0.00244 11.0387 0.0009 1.008 
Development of CHF 1 2.04171 0.13971 213.5536 <.0001 7.704 
Development of diabetes 1 0.22754 0.41488 0.3008 0.5834 1.256 
Number of HTN 
medications 
1 -0.04488 0.04860 0.8527 0.3558 0.956 
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found to be statistically significant. The final multivariable model is shown in table 4.49 
below. 
 
Table 4.49: Multivariable model for the model using the AACE definition for the metabolic 
syndrome 
 
 
The hazard ratio for the incidence of any cardiovascular event in the exposed 
group was found to be equal to 0.74 compared to the control group with a 95% C.I. 
(0.541, 1.018) suggesting that the hazard for cardiovascular events for those exposed to 
the drug of interest was only about 74% of the hazard for those who were not exposed 
to ACEI or ARB but was not statistically significant. 
D) Testing the Proportional Hazard Assumption 
 
1) We included interactions between each variable and log (time) to test for the 
proportional hazard assumption (table 4.50). We notice that the age variable may violate 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio (HR) 
95% HR  
Confidence Limits 
Use of ACEI/ARB 1 -0.29815 0.16106 3.4268 0.0641 0.742 0.541 1.018 
SBP 1 0.00593 0.00250 5.6366 0.0176 1.006 1.001 1.011 
Development of CHF 1 1.89384 0.14535 169.7619 <.0001 6.645 4.998 8.835 
Development of diabetes 1 0.23912 0.34468 0.4813 0.4878 1.270 0.646 2.496 
Age  1 0.04538 0.01017 19.8924 <.0001 1.046 1.026 1.067 
Gender (males vs. females) 1 0.58454 0.10956 28.4678 <.0001 1.794 1.447 2.224 
Former smoker vs. never 1 0.23236 0.11628 3.9928 0.0457 1.262 1.004 1.584 
Current smoker vs. never 1 0.75686 0.15629 23.4523 <.0001 2.132 1.569 2.896 
Race (black vs. other) 1 -0.38979 0.20482 3.6216 0.0570 0.677 0.453 1.012 
Income level 1 -0.05666 0.02775 4.1699 0.0411 0.945 0.895 0.998 
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the proportional hazard assumption as its interaction with log (time) was significant (p-
value = 0.015). 
 
Table 4.50: Testing the proportional hazard assumption by including interactions of independent 
variables with time using the AACE definition for the metabolic syndrome 
 
 
2) The proportional hazard assumption was also tested by examining a plot of 
the scaled Schoenfeld residuals from the model without the interactions terms with 
time. Each subplot has a slope essentially equal to zero suggesting that the proportional 
hazard assumption is met for all the variables except for the age variable (see appendix 
B for details). 
3) The proportional hazard assumption was examined using the rank test .We 
notice that the age variable might violate the proportional hazard assumption as shown 
in table 4.51 below. 
Covariate Hazard Ratio 
Standard
Error 
z 
p-
value 
95% Conf. 
Interval 
Use of ACEI/ARB  *log (time) .9999774 .0001525 -0.15 0.882 .9996785 1.000276 
Development of CHF *log(time) .9999753 .0001479 -0.17 0.867 .9996855 1.000265 
Development of diabetes *log (time) .9998096 .0004842 -0.39 0.694 .9988611 1.000759 
SBP *log (time) .9999987 2.36e-06 -0.53 0.594 .9999941 1.000003 
Age *log (time) .9999768 9.55e-06 -2.43 0.015 .9999581 .9999955 
Gender*log (time) .9998254 .0001028 -1.70 0.089 .9996239 1.000027 
Smoking*log (time) .9999639 .0000715 -0.51 0.613 .9998238 1.000104 
Race *log (time) .9999688 .0002186 -0.14 0.887 .9995405 1.000397 
Income level*log (time) 1.000028 .0000259 1.07 0.286 .9999769 1.000079 
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Table 4.51: Testing the proportional hazard assumption by the rank test using the AACE definition 
for the metabolic syndrome 
 
 
 
 
 
 
 
 
 
 
 
 
E) The Modified Multivariable Model 
 
We notice that the age variable may violate the proportional hazard assumption. 
Thus, the final modified model included the interaction between the age and time as 
shown in table 4.52 below. Similar results were generated when age was included as a 
3-level categorical variable. The detailed model is presented in Appendix A. 
 
 
 
 
Variable rho Chi DF p-value 
Use of ACEI/ARB -0.0096 0.04 1 0.849 
Development of CHF -0.008 0.02 1 0.875 
Development of diabetes -0.014 0.08 1 0.777 
SBP -0.026 0.26 1 0.613 
Age -0.123 6.02 1 0.0142 
Gender -0.073 2.04 1 0.154 
Former smoking vs. never -0.072 2.0 1 0.1573 
Current smoking vs. never -0.001 0.0 1 0.983 
Race 0.0006 0.0 1 0.983 
Income 0.061 1.46 1 0.23 
     
Global test  14.05 10 0.171 
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Table 4.52: Modified multivariable model using the AACE definition for the metabolic syndrome 
 
F) Survival Plot 
 
Cox regression survival plot for the multivariable model is presented in figure 
4.12 below. Survival estimates for the exposed group (exposed to ACEI/ARB) are 
marginally higher than the control group. 
  
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio (HR) 
95% HR  
Confidence Limits 
Use of ACEI/ARB 1 -0.30676 0.16128 3.6176 0.0572 0.736 0.536 1.009 
SBP 1 0.00580 0.00250 5.3571 0.0206 1.006 1.001 1.011 
Development of CHF 1 1.92191 0.14480 176.1644 <.0001 6.834 5.145 9.077 
Development of diabetes 1 0.19104 0.34478 0.3070 0.5795 1.211 0.616 2.379 
Age  1 0.25336 0.06808 13.8497 0.0002 1.288 1.127 1.472 
Gender (male vs. female) 1 0.57147 0.10999 26.9970 <.0001 1.771 1.427 2.197 
Former smoker vs. never 1 0.22036 0.11633 3.5881 0.0582 1.247 0.992 1.566 
Current smoker vs. never 1 0.75682 0.15628 23.4507 <.0001 2.131 1.569 2.895 
Race (black vs. other) 1 -0.38179 0.20490 3.4720 0.0624 0.683 0.457 1.020 
Income level at baseline 1 -0.05270 0.02772 3.6135 0.0573 0.949 0.898 1.002 
Age *log (time) 1 -0.02929 0.00953 9.4377 0.0021 0.971 0.953 0.989 
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Figure 4.12: Cox regression survival plot using the AACE definition for the 
metabolic syndrome 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
G) Influence Diagnostics 
G.1 Deviance residuals 
Deviance residuals are presented in figure 4.13 below. None of the observations 
seem to be of a striking distance between the other points indicating that there do not 
appear to be any outliers. 
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Figure 4.13: Deviance residuals plot using the AACE definition for the metabolic 
syndrome 
 
 
 
G.2 DFBETA statistic 
DFBETA was calculated for each variable and none of the variables had 
exceptionally large values for any of the DFBETAs; all DFBETAs were less than 2. 
DFBETA for the use of ACEI/ARB ranged from -0.017 to 0.025; -0.017 to 0.021 for 
CHF; -0.045 to 0.12 for diabetes; -0.0003 to 0.0004 for SBP; -0.14 to 0.082 for age; -
0.011 to 0.01 for gender; -0.0098 to 0.0094 for former smoking; -0.02 to 0.021 for 
current smoking; -0.014 to 0.04 for race; -0.0035 to 0.0032 for income; -0.014 to 0.023 
for the interaction between age and time. Thus, we may conclude that there were no 
unusually influential observations. 
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Specific Aim 2:  Identify the effect of ACEI/ARB on the long 
term development of cardiovascular events in elderly non-
diabetic hypertensive patients with insulin resistance. 
 
A) Consideration of Age as Independent Variable 
 
Age was tested for its linear relationship with the hazard to incident 
cardiovascular event. The -2 log likelihood was compared between the model with age 
as a linear continuous variable (-2 log likelihood = 5432.072) and the model where age 
was treated as a 13-level categorical variable (-2 log likelihood = 5415.161). The 
difference in -2 log likelihood was equal to 16.91 which was less than א 211, 0.05= 19.68 
suggesting no trend for non-linearity. Therefore, age was included in the analysis as a 
continuous variable. Sensitivity analysis using age as a categorical variable was also 
performed (for details see Appendix A). 
B) Univariate Analysis of the Independent Variables 
 
The following table 4.53 presents the results of the univariate Cox regression 
analyses. The variables that were found to have a statistically significant effect on the 
time to incidence of cardiovascular event included: age, gender, current smokers vs. 
never, race, HDL level, triglycerides, use of aspirin at baseline, BMI at baseline, and 
family history of MI at baseline. Among the time dependent variables, SBP, the total 
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number of antihypertensive medications used and the development of CHF were 
significantly associated with the outcome. 
Table 4.53: Univariate analyses for specific aim 2 using the upper quartile of HOMA to define 
insulin resistance 
 
C) The Multivariable Model 
 
After adjusting for the other variables, the following variables (level of HDL, 
triglycerides level, BMI, race, use of aspirin, and family history of MI at baseline) lost 
their significant effect. However, LDL level at baseline was found to be significantly 
associated with the time to develop any cardiovascular event after adjusting for other 
Variable DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio 
Age  1 0.058 0.0097 35.58 <0.0001 1.06 
Gender (male vs. female) 1 0.558 0.0998 31.289 < 0.0001 1.748 
Smoking(former vs. never) 1 0.20226 0.10835 3.4846 0.0619 1.224 
Smoking(current vs. never) 1 0.64079 0.14915 18.4578 <.0001 1.898 
Race (black vs. other) 1 -0.28901 0.18033 2.5687 0.1090 0.749 
# alcohol beverages 1 0.00487 0.00718 0.4606 0.4974 1.005 
Aspirin use  1 0.16493 0.10585 2.4280 0.1192 1.179 
Exercise Intensity level 1 0.06582 0.06402 1.0571 0.3039 1.068 
BMI  1 -0.01833 0.01279 2.0540 0.1518 0.982 
Income level  1 -0.00924 0.02561 0.1302 0.7183 0.991 
Family hx of MI 1 0.13231 0.10756 1.5130 0.2187 1.141 
Triglycerides 1 0.00100 0.0008296 1.4568 0.2274 1.001 
HDL  1 -0.01176 0.00381 9.5133 0.0020 0.988 
LDL  1 0.00105 0.00147 0.5104 0.4750 1.001 
Time dependent covariates 
Use of ACEI/ARB  1 -0.06190 0.15761 0.1542 0.6945 0.940 
SBP 1 0.00722 0.00244 8.7461 0.0031 1.007 
Development of diabetes 1 0.34268 0.32309 1.1249 0.2889 1.409 
Development of CHF 1 1.73429 0.14487 143.3086 <.0001 5.665 
Number of HTN  
medications 
1 -0.05733 0.04800 1.4264 0.2323 0.944 
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variables. The total number of anti-hypertensives was found to have a confounding 
effect in the model. The final model included our variable of interest, the variables with 
a significant effect, as well as any variables that were found to confound the results. We 
tested for different interactions between exposure to ACEI/ ARB with race, age and 
gender. However, none of these interactions had any significant effects. The final model 
is presented in table 4.54 below. 
Table 4.54: Multivariable model for specific aim 2 using the upper quartile of HOMA to define 
insulin resistance 
 
The multivariable Cox model shows that the hazard ratio for the incidence of 
any cardiovascular event in the exposed group was found to be equal to 0.81 compared 
to the control group with a 95% C.I. (0.58, 1.13); suggesting that the hazard for 
cardiovascular events for those exposed to the drug of interest was only about 81 % of 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
(HR) 
95% HR 
Confidence 
Limits 
Use of ACEI/ARB 1 -0.20914 0.17000 1.5135 0.2186 0.811 0.581 1.132 
SBP 1 0.00630 0.00247 6.4828 0.0109 1.006 1.001 1.011 
Development of 
CHF 
1 1.62256 0.14965 117.5510 <.0001 5.066 3.778 6.793 
Development of 
diabetes 
1 0.50339 0.32709 2.3685 0.1238 1.654 0.871 3.141 
Number of HTN 
medications 
1 -0.05656 0.05146 1.2078 0.2718 0.945 0.854 1.045 
Age 1 0.04919 0.00987 24.8525 <.0001 1.050 1.030 1.071 
Gender (male vs. female) 1 0.55373 0.10690 26.8311 <.0001 1.740 1.411 2.145 
Former smoker vs. never 1 0.09733 0.11339 0.7368 0.3907 1.102 0.883 1.377 
Current smoker vs. never 1 0.58948 0.15148 15.1442 <.0001 1.803 1.340 2.426 
Race 
(black vs. other) 
1 -0.29170 0.18273 2.5485 0.1104 0.747 0.522 1.069 
LDL 1 0.00397 0.00155 6.5592 0.0104 1.004 1.001 1.007 
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the hazard for those who were not exposed to ACEI or ARB. However, that association 
was not statistically significant. 
D) Testing the Proportional Hazard Assumption: 
 
1) We tested for the proportional hazard assumption by including interactions 
between each variable and log (time). Table 4.55 shows the interactions without the 
main effect as well as the estimated coefficients, standard errors, Wald statistics and p-
values for the Wald statistics. Wald test for each interaction with time was not 
statistically significant except for gender and the total number of antihypertensive 
medications used. Therefore, it seems that these 2 variables need to be incorporated in 
the model along with their interactions with log (time). 
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Table 4.55: Testing the proportional hazard assumption by including the interactions of 
independent variables with time for specific aim 2 
 
 
2) The proportional hazard assumption was also tested by examining a plot of 
the scaled Schoenfeld residuals from the model without the interactions terms with 
time. Each subplot has a slope essentially equal to zero except for 2 variables (gender 
and number of antihypertensive medications) suggesting that the proportional hazard 
assumption was met for all the variables except for these 2 variables.(see appendix B 
for details). 
3) The proportional hazard assumption was examined using the rank test as 
shown in table 4.56 below. Similarly, we find that gender and total number of 
antihypertensive medications used may violate the proportional hazard assumption. 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
(HR) 
95% HR Confidence 
Limits 
Use of ACEI/ARB 
*log(time) 
1 -0.21688 0.19755 1.2052 0.2723 0.805 0.547 1.186 
SBP*log(time) 1 -0.00175 0.00274 0.4048 0.5246 0.998 0.993 1.004 
Development of 
CHF*log(time) 
1 -0.11317 0.19887 0.3238 0.5693 0.893 0.605 1.319 
Development of 
diabetes*log(time) 
1 0.14597 1.07086 0.0186 0.8916 1.157 0.142 9.439 
Gender*log(time) 1 -0.27543 0.12730 4.6815 0.0305 0.759 0.592 0.974 
Never Smoking*log(time) 1 0.18752 0.17057 1.2086 0.2716 1.206 0.863 1.685 
Former 
Smoking*log(time) 
1 0.00344 0.16218 0.0004 0.9831 1.003 0.730 1.379 
Race*log(time) 1 -0.02112 0.20920 0.0102 0.9196 0.979 0.650 1.475 
LDL*log(time) 1 -0.0006868 0.00173 0.1581 0.6910 0.999 0.996 1.003 
Number of HTN 
medications 
*log(time) 
1 0.13791 0.06296 4.7978 0.0285 1.148 1.015 1.299 
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Table 4.56: Testing the proportional hazard assumption using the rank test for specific aim 2 
 
E) The Modified Multivariable Model 
 
Gender and total number of antihypertensive medications used may violate the 
proportional hazard assumption and thus their interactions with time need to be included 
to the model as shown in table 4.57 below. Exposure to either ACEI/ARB had no 
statistically significant effect on the incidence of cardiovascular events using the 
HOMA definition for insulin resistance. The hazard ratio for the incidence of any 
cardiovascular event in the exposed group was found to be equal to 0.78 compared to 
the control group with a 95% C.I. (0.56, 1.09) suggesting that the hazard for 
cardiovascular events for those exposed to the drug of interest was not statistically 
Variable rho Chi DF p-value 
Use of ACEI/ARB  -0.044 0.85 1 0.357 
Development of CHF    0.0099 0.04 1 0.84 
Development of diabetes    0.0024 0.0 1 0.96 
SBP    -0.021 0.18 1 0.6672 
Age -0.093 3.39 1 0.066 
Number of HTN 
medications  
0.104 4.69 1 0.0304 
Gender    -0.095 3.66 1 0.056 
Former smoker vs. never smoker  -0.099 3.93 1 0.0473 
Current smoker vs. never smoker  -0.046 0.85 1 0.36 
Race    -0.041 0.69 1 0.41 
LDL  -0.026 0.3 1 0.58 
     
Global test  18.97 11 0.062 
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different from the hazard for those who were not exposed to ACEI or ARB for the 
subjects in the upper quartile of HOMA. 
 
 
Table 4.57: Interactions of the gender and total number of antihypertensive medications with log 
(time) added to the model for specific aim 2 
 
F) Survival Plot 
 
Cox regression survival plot for the multivariable model is presented in figure 
4.14 below. Survival estimates for the exposed group (exposed to ACEI/ARB) were not 
significantly higher than the control group. 
 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-
value 
Hazard 
Ratio 
(HR) 
95% HR 
Confidence Limits 
Use of ACEI/ARB 1 -0.24721 0.17173 2.0722 0.1500 0.781 0.558 1.093 
SBP 1 0.00626 0.00247 6.4341 0.0112 1.006 1.001 1.011 
Development of CHF 1 1.63010 0.14998 118.1242 <.0001 5.104 3.804 6.849 
Development of diabetes 1 0.48882 0.32750 2.2278 0.1355 1.630 0.858 3.098 
Number of  HTN 
medications 
1 -0.87803 0.43259 4.1197 0.0424 0.416 0.178 0.970 
Age 1 0.04936 0.00986 25.0553 <.0001 1.051 1.030 1.071 
Gender 1 2.77431 0.86782 10.2201 0.0014 16.028 2.925 87.812 
Former smoking 1 -0.59222 0.15147 15.2865 <.0001 0.553 0.411 0.744 
Current smoking 1 -0.49552 0.15182 10.6528 0.0011 0.609 0.452 0.820 
Race (black vs. other) 1 -0.26712 0.18283 2.1346 0.1440 0.766 0.535 1.096 
LDL 1 0.00406 0.00155 6.8504 0.0089 1.004 1.001 1.007 
Gender*log(time) 1 -0.30742 0.11888 6.6871 0.0097 0.735 0.583 0.928 
Number of HTN 
medications*log(time) 
1 0.11360 0.05894 3.7140 0.0540 1.120 0.998 1.257 
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Figure 4.14: Cox regression survival plot for specific aim 2 
 
 
 
G) Influence Diagnostics 
G.1 Deviance residuals 
Deviance residuals are presented in figure 4.15 below. None of the observations 
seem to be of a striking distance from the other points indicating that there do not 
appear to be any outliers. 
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Figure 4.15: Deviance residuals plot for specific aim 2 
 
 
G.2 DFBETA statistic 
DFBETA was calculated for each variable and none of the variables had 
exceptionally large values for any of the DFBETAs; all DFBETAs were less than 2. 
DFBETA for the use of ACEI/ARB ranged from -0.017 to 0.028; -0.01 to 0.022 for 
CHF; -0.041 to 0.11 for diabetes; 0.0035 to 0.0004 for SBP; -0.064 to 0.11 for the 
number of anti-hypertensives; -0.031 to 0.018 for age; -0.33 to 0.083 for gender; -0.009 
to 0.0096 for former smoking; -0.0095 to 0.019 for current smoking, -0.01 to 0.033 for 
race; -0.0002 to 0.0003 for LDL; -0.011 to 0.044 for the interaction between gender and 
time; -0.015 to 0.01 for the interaction between the number of anti-hypertensives and 
time. Thus, we may conclude that there were no unusually influential observations. 
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Summary of the Results for the Primary Outcome of Interest 
 
Table 4.58 below shows a summary for the effect of ACEI/ARB on the primary 
outcome: the development of the first incident cardiovascular event including MI, 
claudication, stroke, TIA, angina, angioplasty, CABG, ECG MI or death due to CHD in 
elderly hypertensive non-diabetic individuals using different criteria for the definition of 
metabolic syndrome or insulin resistance. 
 
Table 4.58: Summary of the results for the primary outcome of interest 
 
 
Results for the Effect of Using ACEI/ARB on the Secondary 
Outcomes of Interest 
 
Results for the different secondary outcomes according to the different 
definitions of the metabolic syndrome and according to the insulin resistance definition 
measured by being in the upper quartile of HOMA after adjusting for the different 
covariates, possible confounders and interactions are shown in table 4.59 below. The 
secondary outcomes included development of each of the following definite incident 
events separately: MI, claudication, stroke, TIA, angina, angioplasty, CABG, ECG MI 
Criteria 
Sample 
Size 
Hazard ratio (HR) for using 
ACEI/ARB 
95 % HR Confidence 
Limits 
p 
value 
WHO 990 0.682 (0.48, 0.966) 0.0311 
EGIR 749 0.899 (0.605, 1.335) 0.598 
ATP Ш 777 0.652 (0.433, 0.984) 0.04 
AACE 1102 0.742 (0.541, 1.017 ) 0.0635 
Upper quartile of 
HOMA 
1216 0.779 (0.557, 1.09) 0.1464 
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(silent MI), CHD (development of MI, or angina, or ECG MI, or CHD death), CVA 
(development of stroke, or TIA).  
Different results were observed according to the criteria used to define the 
insulin resistance. Exposure to ACEI/ARB was found to have a protective effect against 
the development of MI in elderly hypertensive subjects with evidence of insulin 
resistance by being in the upper quartile of HOMA, but not in subjects who satisfied the 
different definitions for the metabolic syndrome. The exposure to ACEI/ARB was 
found to have a non-significant effect on the development of stroke, CVA, CABG, ECG 
MI but a significant hazardous effect on the development of TIA in subjects with 
metabolic syndrome according to WHO and AACE criteria. ACE/ARB had a 
significant protective effect against having an angioplasty in subjects in the upper 
quartile of HOMA, and in subjects with metabolic syndrome defined by all criteria 
except for the EGIR criteria. A hazardous effect on the development of claudication 
associated with the use of ACEI/ARB was observed in subjects in the upper quartile of 
HOMA. All the criteria showed a significant protective effect for the use of ACEI/ARB 
against the development of CHD. 
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Table 4.59: Summary of the results for the effect of ACEI/ARB on the secondary outcomes of 
interest in elderly hypertensive non-diabetic subjects using different criteria for the 
definition of the metabolicsyndrome or insulin resistance  
 
Metabolic syndrome / Insulin 
resistance definition 
Hazard ratio (HR) 95 % C.I. p value 
MI 
WHO 0.527 (0.276, 1.008) 0.0529 
EGIR 0.725 (0.332, 1.59) 0.4206 
ATP 0.795 (0.365, 1.73) 0.56 
AACE 0.541 (0.285, 1.028) 0.0606 
HOMA 0.477 (0.23, 0.98) 0.0453 
Stroke 
WHO 0.644 (0.327, 1.27) 0.2038 
EGIR 0.998 (0.492, 2.02) 0.996 
ATP 0.69 (0.299, 1.63) 0.406 
AACE 0.488 (0.235, 1.014) 0.0546 
HOMA 0.824 (0.439, 1.55) 0.5452 
TIA 
WHO 2.2 (1.003, 4.87) 0.0492 
EGIR 1.61 (0.615, 4.22) 0.332 
ATP 1.93 (0.76, 4.89) 0.165 
AACE 2.158 (1.071, 4.34) 0.0314 
HOMA 1.77 (0.796, 3.94) 0.1613 
CVA (stroke/TIA) 
WHO 1.083 (0.655, 1.79) 0.755 
EGIR 1.24 (0.697, 2.19) 0.4701 
ATP 1.17 (0.62, 2.2) 0.623 
AACE 0.97 (0.592, 1.589) 0.903 
HOMA 1.149 (0.703, 1.877) 0.5801 
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Table 4.61 continued 
Metabolic syndrome / insulin 
resistance definition 
Hazard ratio (HR) 95 % C.I. p value 
Angioplasty 
WHO 0.113 (0.015, 0.84) 0.0334 
EGIR 0.17 (0.022, 1.31) 0.0886 
ATP 0.129 (0.017, 0.952) 0.045 
AACE 0.106 (0.014, 0.774) 0.0269 
HOMA 0.101 (0.014, 0.752) 0.0252 
CABG 
WHO 0.55 (0.22, 1.3) 0.189 
EGIR 1.79 (0.68, 4.7) 0.238 
ATP 0.352 (0.107, 1.16) 0.086 
AACE 0.658 (0.292, 1.48) 0.3141 
HOMA 0.863 (0.386, 1.932) 0.7203 
Claudication 
WHO 2.3 (0.991, 5.4) 0.0524 
EGIR 2.35 (0.79, 6.98) 0.123 
ATP 1.97 (0.71, 5.43) 0.19 
AACE 1.36 (0.546, 3.398) 0.5078 
HOMA 3.12 (1.38, 7.09) 0.0065 
ECG MI 
WHO 1.06 (0.22, 5.09) 0.9434 
EGIR 1.51 (0.165, 13.8) 0.7144 
ATP 0.6 (0.075, 4.8) 0.63 
AACE 1.19 (0.341, 4.169) 0.7835 
HOMA 1.16 (0.246, 5.5) 0.8488 
CHD (MI, angina, ECG MI and CHD death) 
WHO 0.49 (0.32, 0.76) 0.0013 
EGIR 0.598 (0.35, 1.008) 0.054 
ATP 0.56 (0.339, 0.93) 0.0264 
AACE 0.61 (0.411, 0.907) 0.0145 
HOMA 0.52 (0.33, 0.798) 0.003 
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Chapter V 
Discussion 
Introduction 
 
Identification of subjects with the metabolic syndrome or insulin resistance may 
provide opportunities to intervene earlier in the development of disease pathways that 
predispose the individuals to both CVD and diabetes. In this observational study we 
assessed the effect of ACEI and/ or ARB on the incidence of CVD as an aggregate in 
hypertensive non-diabetic subjects with the metabolic syndrome or insulin resistance. 
The use of these medications was found to have a significant protective effect against 
the incidence of any CVD when the metabolic syndrome was defined according to the 
ATP and WHO criteria and had only marginally significant protective effect with the 
use of the AACE criteria for the metabolic syndrome. On the other hand, using the 
EGIR criteria and the upper quartile of HOMA, the use of ACEI/ARB had a protective 
trend against the development of CVD but that trend was not statistically significant. 
The effect of ACEI/ARB on the separate cardiovascular endpoints was also 
assessed in elderly hypertensive non-diabetic subjects with evidence of metabolic 
syndrome or insulin resistance. The results differ according to the criteria used to define 
the insulin resistance. However, all of the criteria showed a significant protective effect 
with the use of ACEI/ARB on the incidence of CHD after adjusting for the different 
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possible confounding factors. This suggests that the effect might be different between 
the coronary and non-coronary cardiovascular events. 
Possible Hazardous Effect of ACEI, But Not ARB, On 
Cerebrovascular Accidents 
 
The use of ACEI/ARB was associated with a trend for a protective effect against 
the incidence of different cardiovascular endpoints except for the transient ischemic 
attacks, cerebrovascular accidents and claudication. The hazardous effect of using either 
ACEI/ARB in the results section was prominent in the time to incident TIA, especially 
when the metabolic syndrome was defined according to the AACE and the WHO 
criteria. The effect of using ACEI or ARB on the time to develop TIA was investigated 
and the results are shown in tables 5.1 and 5.2 below. As can be seen, the use of ACEI, 
but not ARB, resulted in a higher hazard to develop TIA when the metabolic syndrome 
was defined according to the WHO and AACE criteria. The high value of the standard 
error for the “use of ARB” and the insignificant p value might be explained by the small 
sample size of ARB users and thus the lack of power to detect a protective or hazardous 
effect of using ARB on the incidence of TIA. The number of subjects on ACEI and 
ARB are presented in tables 5.3 and 5.4 below. 
Table 5.1: Effect of using ACEI or ARB on the time to incidence of TIA event for patients with the 
metabolic syndrome defined by the WHO criteria 
 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio (HR) 
Use of ACEI 1 0.81919 0.40221 4.1482 0.0417 2.269 
Use of ARB  1 -13.13705 1949 0.0000 0.9946 0.000 
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Table 5.2: Effect of using ACEI or ARB on the time to incidence of TIA event for patients with the 
metabolic syndrome defined by the AACE criteria 
 
 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio (HR) 
Use of ACEI 1 0.79574 0.35197 5.1113 0.0238 2.216 
Use of ARB  1 -11.01465 803.75573 0.0002 0.9891 0.000 
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Table 5.3: Number of subjects using ACEI with the metabolic syndrome defined by WHO and AACE criteria 
  
 ACEI  
baseline 
ACEI 
year 1 
ACEI 
year 2 
ACEI 
year 3 
ACEI 
year4 
ACEI 
year 5 
ACEI 
year 6 
ACEI 
year 7 
ACEI 
year 8 
ACEI 
year 9 
ACEI 
year 10 
ACEI 
year 11 
WHO Criteria 
Sample 
size 
(percent 
%) 
109 
(11%) 
108 
(10.9%) 
108 
(10.9%) 
128 
(12.9%) 
139 
(14%) 
156 
(15.8%) 
159 
(16.1%) 
171 
(17.3%) 
202 
(20.4%) 
211 
(21.3%) 
231 
(23.3%) 
237 
(23.9%) 
AACE Criteria 
Sample 
size 
(percent 
%) 
95 
(8.6%) 
94 
(8.5%) 
95 
(8.6%) 
118 
(10.7%) 
134 
(12.2% 
150 
(13.6%) 
156 
(14.2%) 
173 
(15.7%) 
199 
(18.1% 
210 
(19.1%) 
226 
(20.5%) 
236 
(21.4%) 
 
Table 5.4: Number of subjects using ARB with the metabolic syndrome defined by WHO and AACE criteria 
 
 ARB 
baseline 
ARB 
year 1 
ARB 
year 2 
ARB 
year 3 
ARB 
year4 
ARB 
year 5 
ARB 
year 6 
ARB 
year 7 
ARB 
year 8 
ARB 
year 9 
ARB 
year 
10 
ARB 
year 
11 
WHO Criteria 
Sample 
size 
(percent 
%) 
0 
(0%) 
0 
 (0%) 
0 
(0%) 
0 
(0%) 
0 
(0%) 
1 
(0.1%) 
2 
(0.2%) 
5 
(0.5%) 
6 
(0.6%) 
14 
(1.4%) 
27 
(2.7%) 
33 
(3.3%) 
AACE  Criteria 
Sample 
size 
(percent 
%) 
0 
(0%) 
0 
(0%) 
0 
(0%) 
0 
(0%) 
0 
(0%) 
0 
(0%) 
3 
(0.27%) 
6 
(0.54%) 
8 
(0.73%) 
13 
(1.2%) 
24 
(2.2%) 
28 
(2.5%) 
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The hazardous effect of using ACEI on cerebrovascular events is in agreement 
with similar findings that were reported in the literature where patients treated with 
ACEI were found to have more strokes (123-126). It has been suggested that there is an 
apparent reduction of strokes associated with ARB but not ACEI (127;128). One 
possible reason is that ACEIs, but not ARBs, increase the systemic bradykinin level that 
causes vasodilation in both the ischemic and non-ischemic areas of the brain and thus 
might induce a “cerebral steal syndrome” that might exacerbate the cerebral ischemia. 
ARBs prevent the action of angiotensin 2 but ACEI prevent the formation of 
angiotensin 2. It is hypothesized that ARBs selectively block angiotensin 2 subtype 1 
(AT1) and is associated with a reflexive increase in angiotensin 2 and unopposed 
activation of angiotensin 2 subtype 2 receptors. Angiotensin 2 subtype 2 receptors 
which are up-regulated under ischemic conditions induce vasodilation in the collateral 
circulation and thus improve cerebral blood flow. Thus, the result would be reduction in 
the cerebral ischemia without causing the “cerebral steal syndrome”.  
Metabolic Syndrome vs. Insulin Resistance 
 
It has been suggested that some criteria for the metabolic syndrome such as the 
ATP criteria might be highly specific but not a sensitive approach to detect insulin 
resistant subjects (121). This suggests that a substantial number of patients who are 
insulin resistant would not be labeled as “metabolic syndrome patients”. However, a 
large proportion of non-insulin resistant subjects would not satisfy the “metabolic 
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syndrome” criteria. Thus, some of the proposed “metabolic syndrome” criteria might 
not serve as a good screening method to detect insulin resistance. 
What makes the subjects at higher risk for CVD is still unknown: is it the 
underlying insulin resistance or the clustering of different cardiovascular risk factors for 
the metabolic syndrome? Taking that into consideration, we chose to study the effect of 
inhibiting the renin-angiotensin system on 2 different populations: subjects who had a 
clustering of risk factors by satisfying different criteria for the metabolic syndrome, and 
insulin resistant subjects according to the HOMA level as well. We found a significant 
protective effect for the use of ACEI/ARB on the incidence of CVD in elderly 
hypertensive non-diabetic subjects who satisfied the metabolic syndrome definition 
according to the ATP and WHO criteria. However, that association was not significant 
in those who were insulin resistant according to the HOMA level and those who 
satisfied the other definitions of metabolic syndrome. These results might suggest that 
the ATP and WHO criteria might be the best criteria available to identify elderly 
subjects at high CVD risk as suggested by other studies (129). Insulin resistance by 
being in the upper quartile of HOMA might not be the best method to identify elderly 
patients at risk for CVD (130;131). There is still a need for more studies to find the 
criteria that best identify the elderly subjects who are at high risk to develop CVD. 
The Metabolic Syndrome Criteria and Prediction of CVD  
 
The literature has many conflicting results concerning the performance of the 
different available metabolic syndrome definitions in the prediction of cardiovascular 
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events. Some of the proposed criteria might have limited ability to detect subjects at 
high CVD risk; a substantial number of subjects will still be undetected (129). In 
particular, the criteria adopted by AACE and EGIR were found to have a much lower 
discriminatory power among the other criteria including the WHO, and ATP criteria for 
the metabolic syndrome (129). That finding might explain the insignificant results for 
the effect of ACEI/ARB on the CVD when the metabolic syndrome was defined 
according to AACE or EGIR criteria. 
Discrepancy between the Middle Aged and the Elderly 
Population 
 
It has been well established that the metabolic syndrome is associated with 
increased CVD in the middle age population. However, our study involved elderly 
subjects 65 years and older. In the elderly population, some studies have suggested the 
limited predictive utility of the metabolic syndrome to predict total or CVD mortality 
compared with the assessment of only the fasting glucose and blood pressure among the 
other risk factors (132). In other words, the higher risk of cardiovascular mortality 
associated with metabolic syndrome in the elderly was confined to individuals who had 
hypertension or altered glucose metabolism as one of the criteria, suggesting a lower 
impact of the other risk factors such as HDL, triglycerides and waist circumference 
levels. 
It has also been suggested that for the elderly population, many metabolic 
parameters increase with age and thus the threshold of many of these variables need to 
be increased adjusting for these physiological changes. Therefore, in the definition of 
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the metabolic syndrome, higher cut points for the risk factors might be more appropriate 
for risk prediction (120). There is a need for future studies designed specifically to 
define the best criteria with the best cut-points that might predict cardiovascular risk 
and mortality in the elderly population. 
Despite the unavailability of the best criteria to define the metabolic syndrome 
that are predictive of the CVD risk in the elderly population as mentioned above, we 
found a significant protective effect for the use of ACEI/ARB against the development 
of CVD in elderly hypertensive non-diabetic subjects with the metabolic syndrome 
according to the WHO and the ATP criteria. In addition, we found a significant 
protective effect for the use of ACEI/ARB against the development of CHD in the 
elderly hypertensive non-diabetic subjects with the metabolic syndrome according to all 
the available criteria for the metabolic syndrome. 
Validation of the Final Multivariable Models 
 
All of the final multivariable Cox models that assessed the effect of using 
ACEI/ARB, in hypertensive non-diabetic subjects with a diagnosis of the metabolic 
syndrome or evidence of insulin resistance, showed the effects of the other well-
established cardiovascular risk factors as expected. These models showed an increased 
risk of CVD with increased age, male gender, higher SBP, CHF diagnosis, smoking, 
and higher LDL, triglycerides levels and lower income level as expected. 
To validate the conclusions obtained from the multivariable models, we tested 
the effect of using ACEI/ARB on the first incident CVD after adjusting for the use of 
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the other antihypertensive classes of medications by including them as time dependent 
variables in the models (see appendix C for details of the models). In addition, these 
models allowed us to evaluate the effect of each of the following classes of anti-
hypertensives: beta blockers, alpha blockers, calcium channel blockers, diuretics and 
vasodilators on the outcome. None of the new variables had any confounding effect on 
the results. In addition, we found that the use of ACEI/ARB, but not any other 
antihypertensive class of drugs, was associated with a significant protective effect 
against the development of CVD in hypertensive non-diabetic subjects with the 
metabolic syndrome according to the ATP and the AACE criteria. In study 1 (Aim 1) 
which used the WHO definition as criteria for the metabolic syndrome, all the other 
anti-hypertensives were not significantly associated with the outcome. However, 
ACE/ARB use had a protective hazard ratio of 0.68 with a marginally significant p-
value (0.063). These findings strengthen our conclusion that the use of ACEI/ARB 
specifically, among all the antihypertensive medications, might reduce the risk of CVD 
in elderly hypertensive non-diabetic subjects with the metabolic syndrome after 
adjusting for the use of other anti-hypertensives. 
Limitations and Potential Pitfalls 
 
There are certainly some limitations in our study. The obvious primary 
limitation, as any other epidemiological study, is the lack of random assignment of 
subjects to the exposed group. Thus, unmeasured systematic differences between 
patients prescribed ACEI/ARB and those who were not might be potentially present. 
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However, many possible confounding variables were controlled for in the analysis. It 
is also possible that the healthcare providers chose ACEI or ARB for patients who 
were at increased risk of developing CVD such as diabetic and CHF patients. 
Therefore, the development of diabetes and CHF were adjusted for in the model as 
time dependent variables in order to control for possible confounding by indication 
bias.  
The use of ACEI/ARB might need a relatively long period of time to exert 
their cardiovascular protective effect. The duration of exposure to ACEI/ARB for 
some subjects in this study was less than the full follow-up time of the study because 
they were not prescribed these medications at baseline. However, we were able to 
show that the use of ACEI/ARB was associated with lower CVD despite the 
inconsistent duration of exposure which strengthened our conclusion. Another 
possible limitation is that the use of medication was determined using an annual 
medication inventory. Therefore, it is possible that drug exposure might have changed 
during the interval between assessment and any cardiovascular event.  
CVD is known to develop over a long time period. Therefore, it is possible that 
some subjects might have cardiovascular abnormalities that might not be clinically 
evident at baseline, which led to the early development of CVD few years after 
participating in the study. Events prevented in the early years of follow-up may 
indicate that ACEI/ARB not only reduces the incidence of CVD but also might 
modulate the progression of preclinical CVD. Cox regression survival plots using the 
WHO and the ATP criteria to define the metabolic syndrome as shown in figures 4.6 
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and 4.10 show that the survival curves for subjects who had been exposed to 
ACEI/ARB and those using other anti-hypertensives start to separate 1-2 years after 
the start of the follow-up. 
The WHO definition of the metabolic syndrome included the level of 
microalbuminuria as one of the risk criteria. However, it was ignored in our analysis 
as microalbuminuria was not assessed at baseline in the CHS data. Similarly the WHO 
criteria uses the euglycemic clamp as an insulin resistance measure; however we were 
not able to use the euglycemic clamp as the measure of insulin resistance since such 
labor-intensive measures were not available from this large epidemiology dataset. 
HOMA level measurements were used instead. 
Starting from year 12 on, the follow-up data for the subjects were retrieved 
from patients’ self report through phone follow-up interviews. There were no reliable 
measurements of blood pressure, fasting plasma glucose and glucose tolerance test. 
Therefore, the use of the time dependent variables (SBP, development of diabetes and 
CHF) and follow-up event data were limited to the first 11 years of the study.  
Moreover, the results of this study might not be generalizable to patients 
younger than 65 years old as only elderly subjects were included in the database. 
Similarly, volunteer bias cannot be ruled out; as there is a possibility that the cohort of 
5888 subjects who agreed to participate in the CHS study might be different than those 
who did not participate in the study. 
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Conclusion 
 
The effect of ACEI/ARB differs between metabolic syndrome patients and 
patients in the upper quartile of HOMA. In addition, the effect of ACEI/ARB differs 
according to the metabolic syndrome criteria used. Different definitions of the 
metabolic syndrome represent different views regarding the etiology and 
pathophysiology basis of the syndrome. Overall, in elderly hypertensive non-diabetic 
subjects, ACEI/ARB might be protective against the development of CVD in subjects 
who satisfied the WHO and ATP criteria for the metabolic syndrome. There is a 
significant beneficial effect for the use of ACEI/ARB on the CHD specifically in all the 
study subsets. On the other hand, a possible hazardous effect for the development of 
TIA might be associated with the use of ACEI but not ARB. However, there is still a 
need for future studies to establish the criteria that best identify elderly subjects who are 
at increased risk for CVD. 
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Appendix A 
“Presentation of Different Multivariable Models Using 
the Age Variable According to the Classical Geriatric 
Classification” 
 
The age variable was included in the multivariable models above as a linear 
continuous variable if the formal test of linearity was satisfied. Age is usually grouped 
in the elderly according to the classical geriatric classification: (65-74 years), (75-84) 
and (85 years and older). Therefore, the analyses were repeated using age as a 
categorical variable according to the three previously mentioned categories to account 
for any differences between these age groups. Similar results and conclusions regarding 
the multivariable models, testing the proportional hazard assumption and influential 
diagnostics were generated when age was treated as continuous and as categorical. 
Detailed multivariable models using age as a categorical variable are presented below. 
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Table 1: Multivariable model for the EGIR criteria using age as a categorical variable 
 
Parameter DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
P-
value 
Hazard 
Ratio 
(HR) 
95% HR 
Confidence 
Limits 
Use of 
ACEI/ARB 
1 -0.10450 0.20217 0.2672 
0.605
2 
0.901 0.606 1.339 
SBP 1 0.00752 0.00309 5.9245 0.014
9 
1.008 1.001 1.014 
Development 
of CHF 
1 1.56172 0.19166 66.395
2 
<.000
1 
4.767 3.274 6.940 
Development 
of diabetes 
1 0.61650 0.46121 1.7868 0.181
3 
1.852 0.750 4.574 
Number of 
HTN 
medications 
1 -1.15407 0.54696 4.4520 0.034
9 
0.315 0.108 0.921 
Age level (65-
74) 
1 -1.00999 0.46857 4.6461 0.031
1 
0.364 0.145 0.912 
Age level (75-
84) 
1 -0.66394 0.47654 1.9411 0.163
5 
0.515 0.202 1.310 
Gender (male 
vs. female) 
1 0.32870 0.13523 5.9086 
0.015
1 
1.389 1.066 1.811 
Former 
smoking vs. 
never 
1 0.06818 0.14667 0.2161 
0.642
1 
1.071 0.803 1.427 
Current 
smoking vs. 
never 
1 0.74407 0.19134 15.122
9 
0.000
1 
2.104 1.446 3.062 
Race (black 
vs. other) 
1 -0.34051 0.22103 2.3733 
0.123
4 
0.711 0.461 1.097 
Number of 
HTN 
medications 
*log(time) 
1 0.14605 0.07417 3.8774 0.048
9 
1.157 1.001 1.338 
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Table 2: Multivariable model for the ATP criteria using age as a categorical variable 
 
Parameter DF Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
P-
value 
Hazard 
Ratio 
(HR) 
95% HR 
Confidence 
Limits 
Use of 
ACEI/ARB 
1 -0.42014 0.21049 3.9842 0.0459 0.657 0.435 0.992 
Development 
of CHF 
1 2.02094 0.18261 122.476
6 
<.0001 7.545 5.275 10.79 
Development 
of SBP 
1 0.00793 0.00301 6.9343 0.0085 1.008 1.002 1.014 
Development 
of diabetes 
1 0.31719 0.42321 0.5617 0.4536 1.373 0.599 3.148 
Age level 
(65-74) 
1 -0.77645 0.34064 5.1957 0.0226 0.460 0.236 0.897 
Age level 
(75-84) 
1 -0.49789 0.34918 2.0331 0.1539 0.608 0.307 1.205 
Gender 
(male vs. 
female) 
1 0.77303 0.13466 32.9542 <.0001 2.166 1.664 2.821 
Former 
smoker vs. 
never 
1 0.19373 0.14387 1.8132 0.1781 1.214 0.916 1.609 
Current 
Smoker vs. 
never 
1 0.76674 0.18745 16.7311 <.0001 2.153 1.491 3.108 
Race (black 
vs. others) 
1 -0.21540 0.25791 0.6975 0.4036 0.806 0.486 1.337 
Triglycerides 1 0.00263 0.0009776 7.2140 0.0072 1.003 1.001 1.005 
LDL 1 0.00448 0.00184 5.9031 0.0151 1.004 1.001 1.008 
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Table 3: Multivariable model for the AACE criteria using age as a categorical variable 
 
Parameter DF 
Parameter 
 Estimate 
Standard 
Error 
Chi- 
 Square 
P-value 
Hazard 
Ratio 
(HR) 
95% HR 
Confidence 
Limits 
Use of 
ACEI/ARB 
1 -0.30674 0.16139 3.6123 0.0574 0.736 0.536 1.010 
SBP 1 0.00634 0.00252 6.3519 0.0117 1.006 1.001 1.011 
Development 
of CHF 
1 1.92640 0.14519 176.0388 <.0001 6.865 5.165 9.125 
Development 
of diabetes 
1 0.16731 0.34417 0.2363 0.6269 1.182 0.602 2.321 
Age level 
(65-74) 
1 -5.43315 1.41542 14.7345 0.0001 0.004 0.000 0.070 
Age level 
(75-84) 
1 -3.03716 1.39622 4.7318 0.0296 0.048 0.003 0.740 
Gender (male 
vs. female) 
1 0.57877 0.11012 27.6263 <.0001 1.784 1.438 2.214 
Former 
smoking vs. 
never 
1 0.21891 0.11646 3.5331 0.0602 1.245 0.991 1.564 
Current 
smoking vs. 
never 
1 0.74885 0.15663 22.8572 <.0001 2.115 1.556 2.874 
Race (black 
vs. other) 
1 -0.39548 0.20501 3.7213 0.0537 0.673 0.451 1.006 
Income level 
at baseline 
 -0.05234 0.02773 3.5622 0.0591 0.949 0.899 1.002 
Age level (65-
74) *log(time) 
1 0.62059 0.21023 8.7140 0.0032 1.860 1.232 2.808 
Age level (75-
84)*log(time) 
1 0.33475 0.20878 2.5708 0.1089 1.398 0.928 2.104 
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Table 4: Multivariable model for specific aim 2 using age as a categorical variable 
 
 
 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
(HR) 
95% HR 
Confidence 
Limits 
Use of ACEI/ARB 1 -0.25493 0.17192 2.1987 0.1381 0.775 0.553 1.085 
SBP 1 0.00688 0.00247 7.7862 0.0053 1.007 1.002 1.012 
Development of CHF 1 1.64171 0.15032 119.284 <.0001 5.164 3.846 6.933 
Development of  
diabetes 
1 0.43283 0.32711 1.7508 0.1858 1.542 0.812 2.927 
Number of  HTN 
medications 
1 -0.82859 0.43026 3.7088 0.0541 0.437 0.188 1.015 
Age level (65-74) 1 -0.82488 0.31367 6.9156 0.0085 0.438 0.237 0.811 
Age level (75-84) 1 -0.42610 0.31954 1.7781 0.1824 0.653 0.349 1.222 
Gender 1 2.79502 0.86797 10.3696 0.0013 16.363 2.986 89.677 
Former smoking 1 0.09633 0.11368 0.7181 0.3968 1.101 0.881 1.376 
Current smoking 1 0.60474 0.15236 15.7541 <.0001 1.831 1.358 2.468 
Race (black vs. other) 1 -0.28830 0.18298 2.4824 0.1151 0.750 0.524 1.073 
LDL 1 0.00390 0.00156 6.2432 0.0125 1.004 1.001 1.007 
Gender*log(time) 1 -0.30872 0.11891 6.7403 0.0094 0.734 0.582 0.927 
Number of HTN 
medications*log(time) 
1 0.10683 0.05865 3.3173 0.0686 1.113 0.992 1.248 
  155 
 
Appendix B 
“Assessment of the Proportional Hazard Assumption 
Using the Scaled Schoenfeld Residuals” 
 
List of Abbreviations 
Table 5 below presents the list of abbreviations used in the residuals plots. 
 
Table 5: List of abbreviations 
 
 
 
Abbreviation Label 
ars Use of ACE/ARB 
htnmd Number of HTN medications 
Agecatbl, newagecat, 
z 
Age variable 
gendbl Gender  
ldlbl LDL at baseline 
smokebl Smoking at baseline 
trigbl Triglycerides at baseline 
incomebl Income level at baseline 
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Specific Aim 1: Identify the effect of ACEI/ARB on the long 
term development of cardiovascular events in elderly non-
diabetic hypertensive patients with metabolic syndrome. 
Study number 1: The metabolic syndrome defined using the WHO Criteria  
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Study 2: The metabolic syndrome defined using the EGIR Criteria  
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Study number 3:The metabolic syndrome defined using the ATP Criteria  
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Study number 4: The metabolic syndrome defined using the AACE Criteria  
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Specific Aim 2: Identify the effect of ACEI/ARB on the long 
term development of cardiovascular events in elderly non-
diabetic hypertensive patients with insulin resistance. 
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Appendix C 
“Multivariable Models for the Effect of ACEI/ARB 
and the Other Anti-Hypertensives on CVD” 
 
The following multivariable models show the effect of using ACEI/ARB 
adjusting for the use of the other antihypertensive medications on the CVD in elderly 
hypertensive non-diabetic subjects in the upper quartile of HOMA and in subjects 
satisfying the different metabolic syndrome criteria. 
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Specific Aim 1 
Table 6: Effect of different anti-hypertensives on the CVD in patients with the metabolic syndrome 
defined by the WHO criteria 
 
 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p value 
Hazard 
Ratio 
95% HR 
Confidence 
Limits 
Use of 
ACEI/ARB 
1 -0.37947 0.20522 3.4190 0.0644 0.684 0.458 1.023 
Use of beta 
blockers 
1 0.00868 0.18717 0.0021 0.9630 1.009 0.699 1.456 
Use of CCB 1 0.12135 0.18014 0.4538 0.5005 1.129 0.793 1.607 
Use of 
vasodilators 
1 -0.17256 0.30549 0.3191 0.5722 0.842 0.462 1.531 
Use of 
diuretics 
1 0.06333 0.18390 0.1186 0.7306 1.065 0.743 1.528 
Use of alpha 
blockers 
1 -0.06904 0.39816 0.0301 0.8623 0.933 0.428 2.037 
SBP 1 0.00563 0.00259 4.7150 0.0299 1.006 1.001 1.011 
Development 
of CHF 
1 1.80639 0.15764 131.3105 <.0001 6.088 4.470 8.293 
Development 
of diabetes 
1 0.53280 0.36666 2.1115 0.1462 1.704 0.830 3.495 
Number of 
HTN 
medications 
1 -1.45235 0.46504 9.7533 0.0018 0.234 0.094 0.582 
Age 1 0.04216 0.01074 14.77 0.0001 1.042 1.02 1.064 
Gender (male 
vs. female) 
1 0.54102 0.11648 21.5731 <.0001 1.718 1.367 2.158 
Former 
smoker vs. 
never 
1 0.20262 0.12385 2.6764 0.1018 1.225 0.961 1.561 
Current 
smoker vs. 
never 
1 0.69027 0.17051 16.3880 <.0001 1.994 1.428 2.786 
Race (black 
vs. not) 
1 -0.38386 0.20321 3.5683 0.0589 0.681 0.457 1.015 
LDL 1 0.00353 0.00167 4.4739 0.0344 1.004 1.000 1.007 
Number of 
HTN 
medications* 
log(time) 
1 0.18724 0.06326 8.7597 0.0031 1.206 1.065 1.365 
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Table 7: Effect of different anti-hypertensives on the CVD in patients with the metabolic syndrome 
defined by the EGIR criteria 
 
 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p value 
Hazard 
Ratio 
95% HR 
Confidence 
Limits 
Use of 
ACEI/ARB 
1 0.03115 0.24470 0.0162 0.8987 1.032 0.639 1.667 
Use of beta 
blockers 
1 0.44477 0.25046 3.1535 0.0758 1.560 0.955 2.549 
Use of CCB 1 0.34221 0.22611 2.2906 0.1302 1.408 0.904 2.193 
Use of 
vasodilators 
1 0.06439 0.37927 0.0288 0.8652 1.067 0.507 2.243 
Use of 
diuretics 
1 0.20174 0.23694 0.7249 0.3945 1.224 0.769 1.947 
Use of alpha 
blockers 
1 -0.35669 0.52978 0.4533 0.5008 0.700 0.248 1.977 
SBP 1 0.00656 0.00315 4.3395 0.0372 1.007 1.000 1.013 
Development 
of CHF 
1 1.57737 0.19183 67.6150 <.0001 4.842 3.325 7.052 
Development 
of diabetes 
1 0.66936 0.46198 2.0993 0.1474 1.953 0.790 4.830 
Number of 
HTN 
medications 
1 -1.39362 0.57397 5.8954 0.0152 0.248 0.081 0.764 
Age 1 0.05038 0.01276 15.58 <0.0001 1.052 1.026 1.078 
Gender (male 
vs. female) 
1 0.30166 0.13470 5.0155 0.0251 1.352 1.038 1.761 
Former 
smoker vs. 
never 
1 0.09449 0.14644 0.4164 0.5188 1.099 0.825 1.464 
Current 
smoker vs. 
never 
1 0.79649 0.19218 17.1762 <.0001 2.218 1.522 3.232 
Race (black 
vs. not) 
1 -0.35549 0.22278 2.5463 0.1106 0.701 0.453 1.085 
Number of 
HTN 
medications* 
log(time) 
1 0.15737 0.07742 4.1324 0.0421 1.170 1.006 1.362 
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Table 8: Effect of different anti-hypertensives on the CVD in patients with the metabolic syndrome 
defined by the ATP criteria 
 
 
 
  
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p-value 
Hazard 
Ratio (HR) 
95% HR 
Confidence Limits 
Use of ACEI/ARB 1 -0.43939 0.21167 4.3089 0.0379 0.644 0.426 0.976 
Use of beta blockers 1 -0.14595 0.17829 0.6702 0.4130 0.864 0.609 1.226 
Use of CCB 1 -0.08366 0.17483 0.2290 0.6323 0.920 0.653 1.296 
Use of vasodilators 1 -0.15742 0.35214 0.1998 0.6548 0.854 0.428 1.704 
Use of diuretics 1 -0.03537 0.13736 0.0663 0.7968 0.965 0.737 1.263 
Use of alpha blockers 1 -0.12709 0.45738 0.0772 0.7811 0.881 0.359 2.158 
Development of CHF 1 2.02121 0.18241 122.7766 <.0001 7.547 5.279 10.791 
SBP 1 0.00786 0.00307 6.5742 0.0103 1.008 1.002 1.014 
Development of diabetes 1 0.35732 0.42404 0.7101 0.3994 1.429 0.623 3.282 
Age  1 0.0336 0.01281 6.0801 0.0087 1.034 1.009 1.06 
Gender (male vs. female) 1 0.76182 0.13564 31.5469 <.0001 2.142 1.642 2.795 
Former smoker vs. never 1 0.18977 0.14433 1.7288 0.1886 1.209 0.911 1.604 
Current smoker vs. never 1 0.75328 0.18666 16.2863 <.0001 2.124 1.473 3.062 
Race (black vs. other) 1 -0.19095 0.25904 0.5434 0.4610 0.826 0.497 1.373 
Triglycerides 1 0.00276 0.0009732 8.0150 0.0046 1.003 1.001 1.005 
LDL 1 0.00434 0.00184 5.5453 0.0185 1.004 1.001 1.008 
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Table 9: Effect of different anti-hypertensives on the CVD in patients with the metabolic syndrome 
defined by the AACE criteria 
 
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-Square p value 
Hazard 
Ratio (HR) 
95% HR 
Confidence Limits 
Use of ACEI/ARB 1 -0.32097 0.16300 3.8774 0.0489 0.725 0.527 0.999 
Use of diuretics 1 0.00200 0.11233 0.0003 0.9858 1.002 0.804 1.249 
Use of CCB 1 0.11674 0.13849 0.7106 0.3992 1.124 0.857 1.474 
Use of Beta blockers 1 -0.09575 0.15264 0.3935 0.5305 0.909 0.674 1.226 
Use of vasodilators 1 -0.16291 0.27172 0.3595 0.5488 0.850 0.499 1.447 
Use of alpha blockers 1 -0.16457 0.37766 0.1899 0.6630 0.848 0.405 1.778 
SBP 1 0.00599 0.00256 5.4624 0.0194 1.006 1.001 1.011 
Development of CHF 1 1.91875 0.14621 172.2144 <.0001 6.812 5.115 9.073 
Development of diabetes 1 0.18039 0.34528 0.2730 0.6014 1.198 0.609 2.356 
Age 1 0.25274 0.06813 13.763 0.0002 1.288 1.127 1.47 
Gender (male vs. female) 1 0.57574 0.11062 27.0891 <.0001 1.778 1.432 2.209 
Former smoker vs. never 1 0.21010 0.11711 3.2184 0.0728 1.234 0.981 1.552 
Current smoker vs. never 1 0.74766 0.15660 22.7951 <.0001 2.112 1.554 2.871 
Race (black vs. other) 1 -0.39597 0.20673 3.6688 0.0554 0.673 0.449 1.009 
Income level at baseline 1 -0.05359 0.02783 3.7083 0.0541 0.948 0.898 1.001 
Age *log(time) 1 -0.02934 0.00954 9.4679 0.0021 0.971 0.953 0.989 
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Specific aim 2 
Table 10: Effect of different anti-hypertensives on the CVD in specific aim 2 study 
 
 
  
Parameter DF 
Parameter 
Estimate 
Standard 
Error 
Chi-
Square 
p-value 
Hazard 
Ratio 
(HR) 
95% HR 
Confidence Limits 
Use of ACEI/ARB 1 -0.20123 0.19725 1.0407 0.3076 0.818 0.556 1.204 
Use of beta blockers 1 0.03593 0.18884 0.0362 0.8491 1.037 0.716 1.501 
Use of CCB 1 0.25517 0.17746 2.0676 0.1505 1.291 0.912 1.828 
Use of vasodilators 1 0.03626 0.29586 0.0150 0.9025 1.037 0.581 1.852 
Use of diuretics 1 0.22808 0.18033 1.5997 0.2059 1.256 0.882 1.789 
Use of alpha blockers 1 -0.04678 0.39434 0.0141 0.9056 0.954 0.441 2.067 
SBPI 1 0.00620 0.00255 5.9146 0.0150 1.006 1.001 1.011 
Development of CHF 1 1.91116 0.14677 169.5563 <.0001 6.761 5.071 9.014 
Development of diabetes 1 0.25473 0.34566 0.5431 0.4612 1.290 0.655 2.540 
Number of  HTN 
medications 
1 -0.41254 0.41317 0.9969 0.3181 0.662 0.295 1.488 
Age 1 0.0467 0.0101 21.11 <0.0001 1.048 1.027 1.069 
Gender 1 1.70509 0.85084 4.0160 0.0451 5.502 1.038 29.157 
Former smoking 1 0.20770 0.11662 3.1723 0.0749 1.231 0.979 1.547 
Current smoking 1 0.77613 0.15601 24.7478 <.0001 2.173 1.601 2.950 
Race (black vs. other) 1 -0.26310 0.20180 1.6998 0.1923 0.769 0.518 1.142 
LDL 1 0.00331 0.00157 4.4558 0.0348 1.003 1.000 1.006 
Gender*log(time) 1 -0.15632 0.11677 1.7922 0.1807 0.855 0.680 1.075 
Number of HTN 
medications*log(time) 
1 0.03578 0.05663 0.3992 0.5275 1.036 0.928 1.158 
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